Treatment of ENPP1 and ABCC6 deficiencies

JP2024500285A5Inactive Publication Date: 2024-11-26INOZYME PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530251
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-08-26
Filing Date
2021-11-19
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides specific dosages of ENPP1 agents for the in vivo treatment of ENPP1 deficiency, including, inter alia, the treatment of pathological calcification, such as generalized arterial calcification of infancy (GACI), autosomal recessive hypophosphatemic rickets 2 (ARHR2), and other diseases resulting from ENPP1 deficiency, ABCC6 deficiency, and diseases or disorders involving ectopic calcification of soft tissues in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Patent Application No. 63 / 116,086, entitled "Treatment of ENPP1 Deficiency," filed on November 19, 2020 (Attorney Docket No. 4427-10901), U.S. Provisional Patent Application No. 63 / 116,093, entitled "Treatment of diseases of pathological calcification," filed on November 19, 2020 (Attorney Docket No. 4427-11201), U.S. Provisional Patent Application No. 63 / 116,106, entitled "Treatment of ABCC6 Deficiency," filed on November 19, 2020 (Attorney Docket No. 4427-11001), and U.S. Provisional Patent Application No. 63 / 116,106, entitled "Treatment of ENPP1 Deficiency," filed on July 7, 2021 (Attorney Docket No. 4427-11301). No. 63 / 219,229, entitled "Treatment of ABCC6 Deficiency," filed on August 26, 2021 (Attorney Docket No. 4427-10903), and U.S. Provisional Patent Application No. 63 / 237,351, entitled "Treatment of ABCC6 Deficiency," filed on August 26, 2021 (Attorney Docket No. 4427-11003), all of which are incorporated by reference in their entireties herein.

[0002] The field of the invention relates to the treatment of ENPP1 deficiency and ABCC6 deficiency by enzyme replacement.

[0003] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy, created on November 19, 2021, is named 4427-10902_sequence_ST25.txt and is 93.112 bytes in size. [Background technology]

[0004] Calcification in biological systems is a complex process in which calcium salts are maintained at higher concentrations in non-circulating matrices than in local circulating fluids or other moving fluids. The primary result of normal calcification is a concentration of calcium and related inorganic salts in a similar arrangement of crystalline patterns, as well as chemical composition in specialized intercellular matrices, all of which can vary among different species. The net effect of pathological calcification is a greater than normal range of concentrations of calcium and related inorganic salts in a diversity of chemical compositions or patterns, not only in these specialized matrices, but also in other intercellular, extracellular, and cellular materials leading to several disease states.

[0005] Some common examples of disease states of pathological calcification include, but are not limited to, kidney and bladder stones, dental pulp stones, gallstones, salivary gland stones, chronic calculous prostatitis, testicular microcalcification, calcification in hemodialysis patients, atherosclerosis, malakoplakia, scleroderma (systemic sclerosis), calcinosis cutis, calcific aortic stenosis, calcific tendinitis, synovitis and arthritis, diffuse idiopathic osteophytosis, juvenile dermatomyositis, generalized arterial calcification of infancy (GACI), ossification of the posterior longitudinal ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaque, chronic kidney disease (CKD), end stage renal failure (ESRD), pseudoxanthoma elasticum (PXE), ankylosing spondylitis, arteriosclerosis, calciphylaxis, and systemic lupus erythematosus.

[0006] ENPP1 deficiency is a rare genetic disorder caused by inactivating mutations in the ENPP1 gene, which encodes the ENPP1 enzyme. ENPP1 is an integral transmembrane protein whose extracellular domain carries pyrophosphatase and phosphodiesterase activities. ENPP1 converts extracellular ATP to inorganic pyrophosphate (PPi) and AMP.

[0007] ENPP1 deficiency causes hypopyrophosphatemia and hypoadenosinemia, which in turn leads to ectopic (especially arterial) calcification (described in the literature as generalized arterial calcification of infancy [GACI]), skeletal dysfunction secondary to rickets and osteomalacia (described in the literature as autosomal recessive hypophosphatemic rickets 2 [ARHR2]), and obstructive neointimal proliferation. No targeted therapy exists for this disease other than symptomatic and palliative interventions. Thus, ENPP1 deficiency represents an unmet medical need. Infants with ENPP1 deficiency have a high mortality rate in the first 0-6 months of life, and children and adults with ENPP1 deficiency experience a continuing risk of debilitating rickets that progresses to osteomalacia in adulthood with organ calcification and dysfunction, severe bone and joint pain, fatigue, muscle weakness, and repeated fractures, all conditions that lead to reduced quality of life and function. Hypopyrophosphatemia causes increased fibroblast growth factor 23 (FGF23) reactivity, leading to hyperphosphaturia, an essential feature in the pathophysiology of ENPP1 deficiency (the "biochemical axis" of ENPP1 deficiency).

[0008] ENPP1 deficiency is characterized biochemically by low plasma PPi levels and clinically by vascular calcification in infants (GACI phenotype) and infantile and postintimal hyperplasia rickets (ARHR2 phenotype). GACI (generalized arterial calcification of infancy) is a severe disease that occurs in infants and is associated with widespread arterial calcification (Albright, et al., 2015, Nature Comm. 10006).

[0009] ABCC6 deficiency is a rare, inherited, genetic inborn error of metabolism caused by mutations in the ABCC6 gene. ABCC6 deficiency is inherited as a recessive trait in which gene mutations result in reduced or absent activity of the ABCC6 protein (also known as MRP6 (multidrug resistance protein 6), ATP-binding cassette subfamily C member 6 (ABCC6), and multiselective organic anion transporter E (MOAT-E)). The deficiency results in low plasma levels of PPi and is associated with pathological calcification in blood vessels and soft tissues throughout the body, resulting in significant morbidity, including blindness, life-threatening cardiovascular complications, and generalized calcification of the skin. The pathological calcification associated with ABCC6 deficiency is the result of ectopic calcification in elastic fibers, a component of connective tissue, which provides strength and flexibility to structures throughout the body. Ectopic calcification can affect the function of the eye, blood vessels, and elastic fibers in the skin, and less frequently in other areas such as the gastrointestinal tract.

[0010] Mutations in ABCC6 cause pseudoxanthoma elasticum (PXE). [9] The most common mutations, R1141X and 23-29del, account for approximately 25% of identified mutations. Le Saux O,et al.(2001).“A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum”.Am.J.Hum.Genet.69(4):749-64.Pfendner EG,et al.(2007). “Mutation Detection in the ABCC6 Gene and Genotype-Phenotype Analysis in a Large International Case Series Affected by Pseudoxanthoma Elasticum”.Journal of Medical Genetics.44(10):621-8.

[0011] Early atherosclerosis is also associated with mutations in the ABCC6 gene, even in the absence of PXE. Trip MD, et al. (2002) “Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease”. Circulation. 106 (7): 773-5.

[0012] Deficiency of ABCC6 in a mouse model of ischemia results in larger infarcts, which can be rescued by overexpression of ABCC6. Mungrue IN,et al.(2011)."ABCC6 deficiency causes increased infarct size and apoptosis in a mouse cardiac ischemia-reperfusion model".Arterioscler Thromb Vasc Biol.31(12):2806-12.

[0013] Some infants with ABCC6 deficiency are diagnosed with a vascular calcification condition that resembles the acute infantile form of ENPP1 deficiency. In older patients, ABCC6 deficiency manifests as pseudoxanthoma elasticum, or PXE, a rare disorder in which individuals develop calcification of soft connective tissues, including the eye, cardiovascular system, and skin. Individuals with PXE often have eye abnormalities, such as changes in the pigment cells of the retina, or angioidal streaks, which occur when small cracks form in Bruch's membrane, an elastic membrane that underlies the retina. Choroidal neovascularization, or subsequent bleeding and scarring of the retina, can also occur, which, together with damage to Bruch's membrane, can cause vision loss. A recent report stated that 37% of PXE patients over the age of 50 experience visual impairment, with 15% becoming legally blind. (Risseeuw S, Ossewaarde-van Norel J, Klayer CCW, Colijn JM, Imhof SM, van Leeuwen R. Visual acuity in pseudoxanthoma elasticum. Retina. 2019;39(8):1580-1587). Pathological calcification of blood vessels that carry blood from the heart to the rest of the body can cause other signs and symptoms of PXE. Ectopic calcification narrows blood vessels, especially in the lower limbs, leading to claudication, a condition characterized by cramping and pain during movement due to reduced blood flow to the arms and legs. Patients with PXE may also have yellowish bumps, called papules, on the neck, armpits, and other areas of the skin surrounding joints. These papules are painful, impair joint movement, and may indicate a generalized, systemic, pathological process of soft tissue calcification.

[0014] PPi is a modulator of bone mineralization and a potent inhibitor of calcium hydroxyapatite crystal deposition, making it essential for the prevention of deleterious soft tissue mineralization.

[0015] PPi functions as a potent inhibitor of ectopic tissue mineralization by binding to nascent hydroxyapatite (HA) crystals, thereby preventing the future growth of these crystals. ENPP1 generates PPi via hydrolysis of nucleotide triphosphate (NTP), progressive ankylosing protein (ANK) transports intracellular PPi to the extracellular space, and tissue-nonspecific alkaline phosphatase (TNAP) removes PPi via direct hydrolysis of PPi to Pi.

[0016] Ectopic tissue calcification is associated with numerous human diseases, including chronic joint disease and acute lethal neonatal syndrome. To prevent unwanted tissue calcification, factors that promote and inhibit tissue calcification must be kept in tight balance. The balance of extracellular inorganic pyrophosphate (PPi) and phosphate (Pi) is a key regulator of ectopic tissue calcification. The activity of three extracellular enzymes, TNAP, ANK, and ENPP1, tightly controls the concentrations of Pi and PPi in mammals at 100 μmM and 2-3 μM, respectively. PPi is a regulator of biocalcification, inhibiting the formation of basic calcium phosphate from amorphous calcium phosphate.

[0017] ENPP1 polypeptide has been shown to be effective in treating certain diseases of ectopic tissue calcification. ENPP1-Fc has been shown to reduce systemic arterial calcification in a mouse model of GACI (generalized arterial calcification of infancy), a severe disease that occurs in infants and involves widespread arterial calcification (Albright, et al., 2015, Nature Comm.10006). Fusion proteins of ENPP1 have also been described to treat severe tissue calcification diseases (see, for example, PCT Publication Nos. 2014 / 126965 and 2016 / 187408), and fusion proteins of ENPP1 that contain negatively charged bone targeting domains have been described to treat GACI (PCT Publication Nos. 2011 / 113027 and 2012 / 125182).

[0018] There are currently no clinically approved treatments for ultra-rare genetic, chronic, progressive, life-threatening diseases in which patients experience devastating effects on multiple body systems, leading to life-threatening or debilitating complications.

[0019] Summary of the Invention The present disclosure relates to administration of an ENPP1 agent to a subject at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject.

[0020] In one aspect, the disclosure relates to administering an ENPP1 agent to a subject having ENPP1 deficiency or a subject having ABCC6 deficiency at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of ENPP1 protein and / or activity in the plasma or tissues of the subject. Physiological levels of ENPP1 activity in plasma or tissues, as used herein, are an amount or concentration of ENPP1 activity sufficient to achieve and maintain physiological levels of PPi in human serum.

[0021] In one aspect, the disclosure relates to administering an ENPP1 agent to a subject with ENPP1 deficiency or a subject with ABCC6 deficiency at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of Pi and / or PPi in the subject's plasma. Physiological levels of Pi and PPi in human serum (and mammals) are 1-3 mM and 2-3 μM, respectively.

[0022] In one aspect, the disclosure relates to a method for preventing or reducing the progression of vascular calcification in a subject having an ENPP1 deficiency or a subject having an ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of vascular calcification in the subject.

[0023] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological calcification in a subject having an ENPP1 deficiency or a subject having an ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of pathological calcification in the subject.

[0024] In one aspect, the disclosure relates to a method for preventing or reducing the progression of tissue calcification in a subject having ENPP1 deficiency or a subject having ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0025] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological ossification in a subject having an ENPP1 deficiency or a subject having an ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0026] In one aspect, the disclosure relates to a method for increasing circulating pyrophosphate (PPi) in a subject having ENPP1 deficiency or a subject having ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

[0027] In one aspect, the disclosure relates to a method for increasing pyrophosphatase activity in a subject having ENPP1 deficiency or a subject having ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

[0028] In one aspect, the disclosure relates to a method for ameliorating one or more symptoms of ENPP1 deficiency in a subject or one or more symptoms of ABCC6 deficiency in a subject, the method comprising administering to a subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby ameliorating one or more symptoms of ENPP1 deficiency or one or more symptoms of ABCC6 deficiency in the subject.

[0029] In one aspect, the disclosure relates to a method for treating a subject having an ENPP1 deficiency or a subject having an ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby treating the subject.

[0030] In one aspect, the disclosure relates to a method wherein the administered dose is 0.2 mg per kilogram of subject.

[0031] In some embodiments, the disclosure relates to methods in which the dose administered is 0.2 (±1-10%) mg per kilogram of subject. For example, the dose can be 0.22 mg / kg (0.2+10% mg / kg), or 0.18 mg / kg (0.2-10% mg / kg), or 0.21 mg / kg (0.2+5% mg / kg), or 0.19 mg / kg (0.2-5% mg / kg), or 0.202 mg / kg (0.2+1% mg / kg), or 0.198 mg / kg (0.2-1% mg / kg).

[0032] In one aspect, the disclosure relates to a method wherein 0.6 mg is administered per kilogram of subject.

[0033] In some embodiments, the disclosure relates to methods in which the dose administered is 0.6 (±1-5%) mg per kilogram of subject. For example, the dose can be 0.63 mg / kg (0.6+5% mg / kg), or 0.57 mg / kg (0.6-5% mg / kg), or 0.624 mg / kg (0.6+4% mg / kg), or 0.576 mg / kg (0.6-4% mg / kg), or 0.618 mg / kg (0.6+3% mg / kg), or 0.582 mg / kg (0.6-3% mg / kg), or 0.612 mg / kg (0.6+2% mg / kg), or 0.588 mg / kg (0.6-2% mg / kg), or 0.606 mg / kg (0.6+1% mg / kg), or 0.594 mg / kg (0.6-1% mg / kg) of the subject.

[0034] In one aspect, the disclosure relates to a method wherein 1.8 mg is administered per kilogram of subject.

[0035] In some embodiments, the disclosure relates to methods in which the dose administered is 1.8 (±1-5%) mg per kilogram of subject. For example, the dose can be 1.89 mg / kg (1.8+5% mg / kg), or 1.71 mg / kg (1.8-5% mg / kg), or 1.872 mg / kg (1.8+4% mg / kg), or 1.728 mg / kg (1.8-4% mg / kg), or 1.854 mg / kg (1.8+3% mg / kg), or 1.746 mg / kg (1.8-3% mg / kg), or 1.836 mg / kg (1.8+2% mg / kg), or 1.764 mg / kg (1.8-2% mg / kg), or 1.818 mg / kg (1.8+1% mg / kg), or 1.782 mg / kg (1.8-1% mg / kg).

[0036] In yet another aspect, the disclosure relates to a method for treating a subject having an ENPP1 deficiency or a subject having an ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent in an amount effective to treat or otherwise ameliorate one or more symptoms associated with ENPP1 deficiency in the subject or ABCC6 deficiency in the subject.

[0037] In some embodiments of any of the methods described herein, the subject may be, for example, a subject who has discontinued (e.g., for at least 14 days prior to treatment with the ENPP1 agent) (or is otherwise not receiving) treatment with one or more (or all) of the following: a bisphosphonate, an anti-FGF23 antibody or FGF23 antagonist, a calcium receptor agonist, an antacid, a corticosteroid, or a PTH suppressor.

[0038] In some embodiments of any of the methods described herein, the subject is a subject who has been pre-treated with one or more statins and / or one or more proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors. Preferably, such pre-treatment includes consistent doses and frequency of the one or more statins and / or one or more PCSK9 inhibitors for 3 or more years prior to treatment with the methods described herein.

[0039] In some embodiments of any of the methods described herein, the subject has not been diagnosed with a malignancy within five years prior to treatment with a method described herein, except for non-melanoma skin cancer and / or cervical intraepithelial neoplasia.

[0040] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent is administered at least once a week.

[0041] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent is administered at least twice a week.

[0042] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent is administered to a subject at least twice a week after an initial dose.

[0043] In one aspect, the disclosure relates to a method wherein the ENPP1 agent is administered subcutaneously.

[0044] In one aspect, the disclosure relates to a method in which the ENPP1 agent is self-administered.

[0045] In one aspect, the disclosure relates to methods administered under a dosing regimen comprising: (a) an initial dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject, and (b) a maintenance dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject, administered twice weekly for about 7 days after the initial dose.

[0046] In one aspect, the disclosure relates to a method, wherein the initial dose of the ENPP1 agent and the maintenance dose of the ENPP1 agent are the same amount.

[0047] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises the catalytic domain of ENPP1.

[0048] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises a nuclease domain of ENPP1.

[0049] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises the extracellular domain of ENPP1.

[0050] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises the catalytic and nuclease domains of ENPP1.

[0051] In one aspect, the disclosure relates to a method wherein the administered ENPP1 agent comprises a heterologous moiety, where the heterologous moiety can be a polypeptide.

[0052] In one aspect, the disclosure relates to a method in which a heterologous moiety increases the circulating half-life of an ENPP1 agent relative to the circulating half-life of an ENPP1 agent lacking the heterologous moiety.

[0053] In one aspect, the disclosure relates to a method wherein the heterologous moiety comprises an Fc region of an immunoglobulin molecule, the immunoglobulin molecule can be a human immunoglobulin molecule, and the immunoglobulin molecule can be an IgG1.

[0054] In one aspect, the disclosure relates to methods where the heterologous moiety comprises albumin, the heterologous moiety comprises serum albumin, and the heterologous moiety comprises human serum albumin.

[0055] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to ENPP1 agents comprising amino acid residues 99 (PSCAKE) to 925 (QED) of SEQ ID NO:1.

[0056] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to ENPP1 agents that include amino acid residues 1 (FTAGLKPSCAKE) to 833 (QED) of SEQ ID NO:3.

[0057] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:2.

[0058] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:3.

[0059] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:4.

[0060] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:5.

[0061] In one aspect, the disclosure relates to a method, wherein a subject has or is suspected of having generalized arterial calcification of infancy (GACI).

[0062] In one aspect, the disclosure relates to a method, wherein a subject has or is suspected of having autosomal recessive hypophosphatemic rickets type 2 (ARHR2).

[0063] In one aspect, the disclosure relates to a method in which a subject has or is suspected of having pseudoxanthoma elasticum (PXE).

[0064] In one aspect, the disclosure relates to a method, wherein a subject has ABCC6 deficiency and exhibits symptoms similar to subjects with autosomal recessive hypophosphatemic rickets type 2 (ARHR2) or generalized arterial calcification of infancy (GACI).

[0065] In one aspect, the disclosure relates to administering an ENPP1 agent to a subject having pathological calcification at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of Pi and / or PPi in the subject's plasma. Physiological levels of Pi and PPi in human serum (and mammals) are 1-3 mM and 2-3 μM, respectively.

[0066] In one aspect, the disclosure relates to a method for preventing or reducing the progression of vascular calcification in a subject having pathological calcification, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of vascular calcification in the subject.

[0067] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological calcification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of pathological calcification in the subject.

[0068] In one aspect, the disclosure relates to a method for preventing or reducing the progression of tissue calcification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0069] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological ossification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0070] In one aspect, the disclosure relates to a method for increasing circulating pyrophosphate (PPi) in a subject having pathological calcification, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

[0071] In one aspect, the disclosure relates to a method for increasing pyrophosphatase activity in a subject having pathological calcification, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

[0072] In one aspect, the disclosure relates to a method for ameliorating one or more symptoms of pathological calcification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby ameliorating one or more symptoms of pathological calcification in the subject.

[0073] In one aspect, the disclosure relates to a method for treating a subject having pathological calcification, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby treating the subject.

[0074] In one aspect, the disclosure relates to a method wherein the administered dose is 0.2 mg per kilogram of subject.

[0075] In some embodiments, the disclosure relates to methods in which the dose administered is 0.2 (±1-10%) mg per kilogram of subject. For example, the dose can be 0.22 mg / kg (0.2+10% mg / kg), or 0.18 mg / kg (0.2-10% mg / kg), or 0.21 mg / kg (0.2+5% mg / kg), or 0.19 mg / kg (0.2-5% mg / kg), or 0.202 mg / kg (0.2+1% mg / kg), or 0.198 mg / kg (0.2-1% mg / kg).

[0076] In one aspect, the disclosure relates to a method wherein 0.6 mg is administered per kilogram of subject.

[0077] In some embodiments, the disclosure relates to methods in which the dose administered is 0.6 (±1-5%) mg per kilogram of subject. For example, the dose can be 0.63 mg / kg (0.6+5% mg / kg), or 0.57 mg / kg (0.6-5% mg / kg), or 0.624 mg / kg (0.6+4% mg / kg), or 0.576 mg / kg (0.6-4% mg / kg), or 0.618 mg / kg (0.6+3% mg / kg), or 0.582 mg / kg (0.6-3% mg / kg), or 0.612 mg / kg (0.6+2% mg / kg), or 0.588 mg / kg (0.6-2% mg / kg), or 0.606 mg / kg (0.6+1% mg / kg), or 0.594 mg / kg (0.6-1% mg / kg) of the subject.

[0078] In one aspect, the disclosure relates to a method wherein 1.8 mg is administered per kilogram of subject.

[0079] In some embodiments, the disclosure relates to methods in which the dose administered is 1.8 (±1-5%) mg per kilogram of subject. For example, the dose can be 1.89 mg / kg (1.8+5% mg / kg), or 1.71 mg / kg (1.8-5% mg / kg), or 1.872 mg / kg (1.8+4% mg / kg), or 1.728 mg / kg (1.8-4% mg / kg), or 1.854 mg / kg (1.8+3% mg / kg), or 1.746 mg / kg (1.8-3% mg / kg), or 1.836 mg / kg (1.8+2% mg / kg), or 1.764 mg / kg (1.8-2% mg / kg), or 1.818 mg / kg (1.8+1% mg / kg), or 1.782 mg / kg (1.8-1% mg / kg).

[0080] In yet another aspect, the disclosure relates to a method for treating a subject having pathological calcification, the method comprising administering to the subject an ENPP1 agent in an amount effective to treat or otherwise ameliorate one or more symptoms associated with pathological calcification in the subject.

[0081] In some embodiments of any of the methods described herein, the subject may be, for example, a subject who has discontinued (e.g., for at least 14 days prior to treatment with the ENPP1 agent) (or is otherwise not receiving) treatment with one or more (or all) of the following: a bisphosphonate, an anti-FGF23 antibody or FGF23 antagonist, a calcium receptor agonist, an antacid, a corticosteroid, or a PTH suppressor.

[0082] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent is administered at least once a week.

[0083] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent is administered at least twice a week.

[0084] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent is administered to a subject at least twice a week after an initial dose.

[0085] In one aspect, the disclosure relates to a method wherein the ENPP1 agent is administered subcutaneously.

[0086] In one aspect, the disclosure relates to a method in which the ENPP1 agent is self-administered.

[0087] In one aspect, the disclosure relates to methods administered under a dosing regimen comprising: (a) an initial dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject, and (b) a maintenance dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject, administered twice weekly for about 7 days after the initial dose.

[0088] In one aspect, the disclosure relates to a method, wherein the initial dose of the ENPP1 agent and the maintenance dose of the ENPP1 agent are the same amount.

[0089] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises the catalytic domain of ENPP1.

[0090] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises a nuclease domain of ENPP1.

[0091] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises the extracellular domain of ENPP1.

[0092] In one aspect, the disclosure relates to a method, wherein the ENPP1 agent comprises the catalytic and nuclease domains of ENPP1.

[0093] In one aspect, the disclosure relates to a method wherein the administered ENPP1 agent comprises a heterologous moiety, where the heterologous moiety can be a polypeptide.

[0094] In one aspect, the disclosure relates to a method in which a heterologous moiety increases the circulating half-life of an ENPP1 agent relative to the circulating half-life of an ENPP1 agent lacking the heterologous moiety.

[0095] In one aspect, the disclosure relates to a method wherein the heterologous moiety comprises an Fc region of an immunoglobulin molecule, the immunoglobulin molecule can be a human immunoglobulin molecule, and the immunoglobulin molecule can be an IgG1.

[0096] In one aspect, the disclosure relates to methods where the heterologous moiety comprises albumin, the heterologous moiety comprises serum albumin, and the heterologous moiety comprises human serum albumin.

[0097] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to ENPP1 agents comprising amino acid residues 99 (PSCAKE) to 925 (QED) of SEQ ID NO:1.

[0098] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to ENPP1 agents that include amino acid residues 1 (FTAGLKPSCAKE) to 833 (QED) of SEQ ID NO:3.

[0099] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:2.

[0100] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:3.

[0101] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:4.

[0102] In one aspect, the disclosed ENPP1 agents and methods of use thereof relate to an ENPP1 agent comprising the amino acid sequence set forth in SEQ ID NO:5.

[0103] In one aspect, the disclosure relates to a method, wherein a subject has or is suspected of having a disease of pathological calcification other than generalized arterial calcification of infancy (GACI).

[0104] In one aspect, the disclosure relates to a method, wherein a subject has or is suspected of having a disease of pathological calcification other than autosomal recessive hypophosphatemic rickets type 2 (ARHR2).

[0105] In one aspect, the disclosure relates to a method in which a subject has or is suspected of having a pathological calcification disease other than pseudoxanthoma elasticum (PXE).

[0106] In one aspect, the disclosure relates to a method for treating a subject suffering from kidney and bladder stones, dental pulp stones, gallstones, salivary gland stones, chronic calculous prostatitis, testicular microcalcification, calcification in hemodialysis patients, atherosclerosis, malakoplakia, scleroderma (systemic sclerosis), ARHR2, calcinosis cutis, calcific aortic stenosis, calcific tendinitis, synovitis and arthritis, diffuse idiopathic osteophytosis, juvenile dermatomyositis, infantile systemic osteoporosis, and the like. The present invention relates to a method for treating or preventing the development of atherosclerosis in a subject having or suspected of having one or more of: chronic arterial calcification (GACI), ossification of the posterior longitudinal ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, chronic kidney disease (CKD), end stage renal disease (ESRD), pseudoxanthoma elasticum (PXE), ankylosing spondylitis, arteriosclerosis, calciphylaxis, and systemic lupus erythematosus.

[0107] In some embodiments of any of the methods described herein, the subject is characterized by one or more of the inclusion criteria described herein. For example, the subject described herein may have a plasma PPi concentration of less than about 1300 nM, for example, before treatment with an ENPP1 agent. In some embodiments, the subject is not characterized by any of the exclusion criteria described herein. For example, the subject may be a subject who does not have advanced ocular disease before or during treatment with an ENPP1 agent. In some embodiments, the subject does not have advanced ocular disease that requires anti-VEGF treatment (for example) before or during treatment with an ENPP1 agent. [Brief description of the drawings]

[0108] [Figure 1] A schematic diagram of ENPP1 deficiency is shown. [Diagram 2] The complete unprocessed amino acid sequence of the wild-type ENPP1 precursor protein (SEQ ID NO:1) is shown. The cytoplasmic and transmembrane regions are underlined. Potential N-glycosylation sites are in bold. PSCAKE (residues 99-104, boxed) marks the beginning of the soluble ENPP1 protein portion that includes SMB1 (residues 104-144) and SMB2 (residues 145-189). [Diagram 3]1 illustrates certain domains of human ENPP1. [Figure 4] The amino acid sequence of the soluble wild-type ENPP1 polypeptide (SEQ ID NO:2) is shown. [Diagram 5] Figures 5A and 5B show multiple alignments of various vertebrate and human soluble ENPP1 polypeptides (SEQ ID NOs: 1 and 7-10). The various soluble ENPP1 polypeptides correspond to the following species and represent regions of specific NCBI accession numbers: mouse (NCBI accession NP_001295256.1, SEQ ID NO: 7), bovine (NCBI accession NP_001193141, SEQ ID NO: 8), rabbit (NCBI accession NP_001162404.1, SEQ ID NO: 9), human (NCBI accession NP_006199.2, SEQ ID NO: 1), and baboon (NCBI accession NP_001076211.2, SEQ ID NO: 10). [Figure 6] FIG. 1 depicts a schematic diagram of ABCC6 deficiency. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0109] definition The terms used herein generally have their ordinary meaning in the art, within the context of this disclosure, and within the specific context in which each term is used. Particular terms are discussed below or elsewhere in this specification to provide additional guidance to the practitioner in describing the compositions and methods of the present disclosure, and how to make and use them. The scope or meaning of any use of a term will be clear from the specific context in which it is used.

[0110] "ENPP1 deficiency" is characterized by a reduced level of ENPP1 enzyme activity in the serum or plasma of a subject. ENPP1 deficiency is a rare genetic disorder caused by inactivating mutations in the ENPP1 gene, which encodes the ENPP1 enzyme. ENPP1 is an integral transmembrane protein whose extracellular domain carries pyrophosphatase and phosphodiesterase activities. ENPP1 converts extracellular ATP to inorganic pyrophosphate (PPi) and AMP.

[0111] ENPP1 deficiency causes hypopyrophosphatemia and hypoadenosinemia, which in turn leads to ectopic (especially arterial) calcification (described in the literature as generalized arterial calcification of infancy [GACI]), skeletal dysfunction secondary to rickets and osteomalacia (described in the literature as autosomal recessive hypophosphatemic rickets 2 [ARHR2]), and obstructive neointimal proliferation. No targeted therapy exists for this disease other than symptomatic and palliative interventions. Thus, ENPP1 deficiency represents an unmet medical need. Infants with ENPP1 deficiency have a high mortality rate in the first 0-6 months of life, and children and adults with ENPP1 deficiency experience a continuing risk of debilitating rickets that progresses to osteomalacia in adulthood with organ calcification and dysfunction, severe bone and joint pain, fatigue, muscle weakness, and repeated fractures, all conditions that lead to reduced quality of life and function. Hypopyrophosphatemia causes increased fibroblast growth factor 23 (FGF23) reactivity, leading to hyperphosphaturia, an essential feature in the pathophysiology of ENPP1 deficiency (the "biochemical axis" of ENPP1 deficiency).

[0112] ENPP1 deficiency is characterized biochemically by low plasma PPi levels and clinically by vascular calcification in infants (GACI phenotype) and infantile and postintimal hyperplasia rickets (ARHR2 phenotype). GACI (generalized arterial calcification of infancy) is a severe disease that occurs in infants and is associated with widespread arterial calcification (Albright, et al., 2015, Nature Comm. 10006).

[0113] The reduced ENPP1 enzyme activity can occur through a reduction in the amount of ENPP1 enzyme present in the serum or plasma of a subject relative to the amount of ENPP1 enzyme present in the serum or plasma of a normal subject, and / or a reduction in the level of ENPP1 enzyme activity detected in the serum or plasma of a subject relative to the level of ENPP1 enzyme activity detected in a normal subject, and / or through a lack of expression of the ENPP1 gene at the transcriptional (RNA and / or mRNA) or translational level, e.g., through a lack of the ENPP1 gene or a regulatory element that affects ENPP1 gene expression relative to the normal expression of the ENPP1 gene in a subject. ENPP1 enzyme activity is defined below.

[0114] "Enzymatically active" with respect to an ENPP1 polypeptide, or as used herein, "enzymatically active" with respect to an ENPP1 polypeptide, is defined as having ATP hydrolysis activity to AMP and PPi, and / or AP3a hydrolyzes to ATP. NPP1 readily hydrolyzes ATP to AMP and PPi. The steady-state Michaelis-Menten enzyme constant of NPP1 is determined using ATP as a substrate. NPP1 can be shown to cleave ATP by HPLC analysis of the enzymatic reaction, and the identity of the substrates and products of the reaction is confirmed using ATP, AMP, and ADP standards. The ATP substrate degrades over time in the presence of NPP1, with the accumulation of the enzyme product AMP. Using various concentrations of ATP substrate, the rate of the initial rate of NPP1 is derived in the presence of ATP, and the data is curve-fitted to derive the enzyme rate constant. At physiological pH, the kinetic rate constant of NPP1 is Km=144 μM and kcat=7.8 s-1.

[0115] As used herein, the term "plasma pyrophosphate (PPi) level" refers to the amount of pyrophosphate present in the plasma of an animal. In certain embodiments, the animals include rats, mice, cats, dogs, humans, cows, and horses. Due to release from platelets, it is necessary to measure PPi in plasma rather than serum. There are several ways to measure PPi, one of which is by an enzyme assay using uridine-diphosphoglucose (UDPG) pyrophosphorylase with modification (Lust & Seegmiller, 1976, Clin. Chim. Acta 66:241-249; Cheung & Suhadolnik, 1977, Anal. Biochem. 83:61-63).

[0116] Typically, plasma PPi levels in healthy human subjects range from about 1 μm to about 3 μM, and in some cases, 1-2 μm. Normal levels of ENPP1 in plasma refer to the amount of ENPP1 protein required to maintain normal levels of plasma pyrophosphate (PPi) in healthy subjects. Normal levels of PPi in healthy humans correspond to 2-3 μM. Subjects with ENPP1 deficiency exhibit low PPi levels ranging from at least 10% below normal, at least 20% below normal, at least 30% below normal, at least 40% below normal, at least 50% below normal, at least 60% below normal, at least 70% below normal, at least 80% below normal, and combinations thereof. In patients afflicted with GACI, PPi levels are found to be below 1 μm, and in some cases below detectable levels. In patients afflicted with PXE, PPi levels are below 0.5 μm. (Arterioscler Thromb Vasc Biol.2014 Sep;34(9):1985-9, Braddock et al., Nat Commun.2015; 6:10006.)

[0117] "ABCC6 deficiency" can be indicated in several ways, for example, by a reduced expression level of ABCC6 enzyme in a subject. A subject with ABCC6 deficiency can be identified by the presence of one or more physiological symptoms, such as ocular calcification, calcified yellow papule, pigmented streaks, visual impairment, calcification of soft connective tissues including the cardiovascular system, and / or the presence of ABCC6 mutations that affect the activity and expression of ABCC6 protein. Details regarding the diagnosis and classification of ABCC6 mutations are known in the art. (Expert Opin Orphan Drugs.2014 Jun 1;2(6):567-577).

[0118] ABCC6 deficiency can result in PXE. Reduced ABCC6 enzyme activity can occur through a reduction in the amount of ABCC6 enzyme present in a subject relative to the amount of ABCC6 enzyme present in a normal subject, and / or a reduction in the level of ABCC6 enzyme activity in a subject relative to the level of ABCC6 enzyme activity detected in a normal subject, and / or through a defect in expression of the ABCC6 gene at the transcriptional (RNA and / or mRNA) or translational level, e.g., a defect in the ABCC6 gene or a regulatory element that affects ABCC6 gene expression relative to the normal expression of the ABCC6 gene in a subject.

[0119] Subjects with ABCC6 deficiency can be identified by screening for ABCC6 gene mutations. Several methods for detecting gene mutations are known in the art. For example, detection of ABCC6 gene mutations can be performed by following the protocol described in J Med Genet. 2007 Oct; 44(10): 621-628. (Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum, Ellen G Pfendner, et al.)

[0120] As used herein, an "ABCC6-deficient patient" or "ABCC6-deficient subject" refers to a patient who has at least one pathogenic mutation in the ABCC6 gene that affects the activity and / or expression of the ABC66 protein.

[0121] "Pathological calcification": As used herein, this term refers to the hardening of the abnormal deposition of calcium salts in soft tissues, secretions, and excretory pathways of the body. There are two types: dystrophic calcification, which occurs in dying and dead tissues, exceeding the homeostatic capacity of cells and tissues, and metastatic calcification (hypercalcemia), which elevates extracellular levels of calcium. Calcification can involve cells as well as extracellular matrix components such as collagen of the basement membrane and elastic fibers of arterial walls. Some examples of tissues prone to calcification include: gastric mucosa - the inner epithelial lining of the stomach, kidneys and lungs, cornea, systemic arteries, and pulmonary veins.

[0122] "Pathological ossification": as used herein, this term refers to a pathological condition in which bone develops in tissues that are not part of the osseous system and in connective tissues that do not normally exhibit osteogenic properties. Ossification is classified into three types depending on the nature of the affected tissue or organ: endochondral ossification is ossification that occurs within and replaces cartilage; intramembranous ossification is ossification that occurs in and replaces connective tissue; deformed ossification is the development of bony material in normally soft body structures, also called heterotopic ossification.

[0123] A "deficiency" in NPP1 refers to a condition in which a subject has less than 5%-10% of the normal level of NPP1 in plasma. Normal levels of NPP1 in healthy human subjects are approximately 10-30 ng / ml. (Am J Pathol. 2001 Feb;158(2):543-554.)

[0124] A "deficiency" of ABCC6 refers to a condition in which a subject has less than 5%-10% of the normal level of ABCC6 expression. ABCC6 protein is expressed in the liver, and levels of ABCC6 protein can be measured by means of a liver biopsy.

[0125] A "low" level of PPi refers to a condition in which a subject has 2% to 5% or less of the normal level of plasma pyrophosphate (PPi). The normal level of plasma PPi in healthy human subjects is approximately 1.8 to 2.6 μM. (Arthritis and Rheumatism, Vol. 22, No. 8 (August 1979))

[0126] "Ectopic calcification" refers to a condition characterized by the pathological deposition of calcium salts in tissues or bone growths in soft tissues.

[0127] "Ectopic soft tissue calcification" refers to inappropriate biomineralization of calcium phosphate, hydroxyapatite, calcium oxalate, and octacalcium phosphate occurring in soft tissues, typically leading to loss of hardening of the soft tissue. "Arterial calcification" refers to ectopic calcification occurring in arteries and heart valves, leading to hardening and / or narrowing of the arteries. Arterial calcification correlates with atherosclerotic plaque burden and increased risk of myocardial infarction, increased ischemic episodes in peripheral vascular disease, and increased risk of dissection after angioplasty.

[0128] "Venous calcification" refers to ectopic calcification occurring in veins, which reduces the elasticity of the veins and restricts blood flow, which in turn can lead to increased blood pressure and coronary artery disease.

[0129] The term "vascular calcification" refers to the pathological deposition of minerals in the vascular system. It has various forms, including intimal calcification and medial calcification, but can also be found in the valves of the heart. Vascular calcification is associated with atherosclerosis, diabetes, certain genetic conditions, and kidney disease, especially CKD. Patients with vascular calcification are at higher risk for adverse cardiovascular events. Vascular calcification affects a wide variety of patients. Idiopathic infantile arterial calcification is a rare form of vascular calcification in which the arteries of newborns become calcified.

[0130] "Cerebral calcification" (BC) refers to a nonspecific neuropathology in which deposition of calcium and other minerals occurs in blood vessel walls and parenchymal tissues, leading to neuronal cell death and gliosis. Cerebral calcification is frequently associated with a variety of chronic and acute brain disorders, including Down's syndrome, Lewy body disease, Alzheimer's disease, Parkinson's disease, vascular dementia, brain tumors, and various endocrine conditions.

[0131] Calcification of cardiac tissue refers to the accumulation of deposits of calcium (which may include other minerals) in cardiac tissue, such as aortic and coronary artery tissue.

[0132] As used herein, the term "chronic kidney disease (CKD)" refers to abnormalities in kidney structure or function that persist for more than 3 months with health effects. In general, excretory, endocrine, and metabolic functions decline together in most chronic kidney diseases. Cardiovascular disease is the most common cause of death in patients with chronic kidney disease (CKD), and vascular calcification is one of the strongest predictors of cardiovascular risk. The prevalence of vascular calcification increases with declining renal function, and calcification occurs several years earlier in CKD patients than in the general population. Prevention, reduction, and / or reversal of vascular calcification may result in increased survival rates for patients with CKD.

[0133] Clinical symptoms of chronic kidney disease include itching, muscle cramps, nausea, lack of appetite, swelling of the feet and ankles, insomnia, and difficulty breathing. Chronic kidney disease, if left untreated, tends to progress to end-stage renal disease (ESRD). Common symptoms of ESRD include inability to urinate, fatigue, lethargy, weight loss, bone pain, changes in skin color, frequent bruising, and swelling of the outer extremities such as fingers, toes, hands, and legs. Calciphylaxis or calcific uremic arteriopathy (CUA) is a condition that causes calcium to accumulate in blood vessels in fat and skin. A subpopulation of patients suffering from ESRD may also develop calciphylaxis. Common symptoms of calciphylaxis include large purple net-like patterns on the skin, deep painful lumps that ulcerate and form open wounds with black-brown crusts that do not heal, and skin lesions in areas with high fat content such as the lower legs or thighs, breasts, buttocks, and abdomen. People with calciphylaxis may have higher than normal levels of calcium (hypercalcemia) and phosphate (hyperphosphatemia) in the blood. They may also have symptoms of hyperparathyroidism, which occurs when the parathyroid glands produce excess parathyroid hormone (PTH). Reduced plasma pyrophosphate (PPi) levels are also present in vascular calcification associated with end-stage renal disease (ESRD).

[0134] Vascular calcification associated with ESRD contributes to poor outcomes by increasing pulse pressure, causing or exacerbating hypertension, and inducing or intensifying myocardial infarction and stroke. It is important to note that the majority of ESRD patients do not die from renal failure, but rather from cardiovascular complications of ESRD, and many very young ESRD patients on dialysis have coronary artery calcification. A histological subtype of CKD-associated vascular calcification is known as Monckeburg sclerosis, a type of vascular sclerosis in which calcium deposits are found in the muscular layer of the medial vessel wall. This form of calcification is identical to the vascular calcification observed in human CKD patients and in rodent models of the disease described herein, but is histologically distinct from the intimal or neointimal vessel wall calcification commonly observed in atherosclerosis.

[0135] As used herein, "generalized arterial calcification of infancy (GACI)" (also known as IACI) refers to a disorder affecting the circulatory system that becomes evident before birth or within the first few months of life. It is characterized by an abnormal buildup (calcification) of the mineral calcium in the walls of blood vessels that carry blood from the heart to the rest of the body (arteries). Calcification often occurs along with a thickening of the inner layer of the arterial wall (intima). These changes lead to narrowing (stenosis) and hardening of the arteries, causing the heart to work harder to pump blood. As a result, heart failure can develop in affected individuals, with signs and symptoms including difficulty breathing, accumulation of fluid in the limbs (edema), a bluish appearance of the skin or lips (cyanosis), severe high blood pressure (hypertension), and an enlarged heart (cardiomegaly). Patients with GACI may also have calcification in other organs and tissues, especially around the joints. In addition, they may have hearing loss, called rickets, or softening and weakening of the bones.

[0136] Generalized arterial calcification (GACI) or idiopathic infantile arterial calcification (IIAC) is characterized by an abnormal buildup (calcification) of the mineral calcium in the walls of blood vessels that carry blood from the heart to the rest of the body (arteries). Calcification often occurs along with a thickening of the inner layer of the arterial wall (intima). These changes lead to narrowing (stenosis) and hardening of the arteries, causing the heart to work harder to pump blood. As a result, heart failure can develop in affected individuals, with signs and symptoms including difficulty breathing, accumulation of fluid in the extremities (edema), a bluish appearance of the skin or lips (cyanosis), severe high blood pressure (hypertension), and an enlarged heart (cardiomegaly).

[0137] As used herein, the term "infant" refers to a human child during the first year of life. Typically, infancy refers to the age during which a child is not yet able to walk.

[0138] As used herein, the term "arterial calcification", or "vascular calcification", or "arteriosclerosis" refers to a process characterized by thickening and loss of elasticity of the muscular arterial wall. The thickening and loss of elasticity occurs at two different sites, the intima and medial layers of the vascular system (medial vascular calcification). Intimal calcification is associated with atherosclerosis, while medial calcification is characterized by vascular sclerosis and arteriosclerosis. This impairs the hemodynamics of the cardiovascular system, reduces the elasticity of the arteries, and increases the propensity for morbidity and mortality.

[0139] As used herein, the term "mineral bone disorder (MBD)" refers to a disorder characterized by abnormal hormone levels, causing calcium and phosphorus levels in a person's blood to become out of balance. Mineral and bone disorders commonly occur in people with CKD, and occur in most people with kidney failure who undergo dialysis.

[0140] Osteopenia is a bone condition characterized by decreased bone density, which leads to bone weakening and increased risk of fracture. Osteomalacia is a bone disorder characterized by decreased mineralization of newly formed bone. Osteomalacia is caused by severe vitamin D deficiency (which can be caused by nutritional or genetic syndromes) and conditions that cause very low blood phosphate levels. Both osteomalacia and osteopenia increase the risk of fracture. Symptoms of osteomalacia include bone pain and muscle weakness, bone tenderness, difficulty walking, and muscle cramps.

[0141] As used herein, "age-related osteopenia" refers to a condition in which bone mineral density is lower than normal. Typically, patients with osteopenia have a bone mineral density T-score of -1.0 to -2.5. If left untreated, osteopenia can progress to osteoporosis, making bones weak and highly susceptible to fracture.

[0142] As used herein, the term "ossification of the posterior longitudinal ligament (OPLL)" refers to a hyperplasia (excessive bone growth) condition that results in ectopic calcification of the posterior longitudinal ligament. The posterior longitudinal ligament connects and stabilizes the bones of the spine. Thickening or calcification of the ligament can compress the spinal cord, resulting in myelopathy. Symptoms of myelopathy include difficulty walking and difficulty with bowel and bladder control. OPLL can also cause radiculopathy, or compression of the nerve roots. Symptoms of cervical radiculopathy include pain, tingling, or numbness in the neck, shoulders, arms, or hands.

[0143] The clinical symptoms and signs caused by OPLL are classified into (1) myelopathy, or spinal cord lesion with motor and sensory disturbances of the upper and lower limbs, spasticity, and bladder dysfunction, (2) cervical radiculopathy with pain and sensory disturbances of the upper limbs, and (3) axial discomfort with pain and stiffness around the neck. The most common early symptoms of OPLL include paresthesias and tingling in the hands, and clumsiness. With the progression of neurological deficits, lower limb symptoms such as difficulty walking may appear. OPLL is detected by lateral plain radiographs, and the diagnosis and morphological details of cervical OPLL are clearly demonstrated by magnetic resonance imaging (MRI) and computed tomography (CT).

[0144] As used herein, the term "pseudoxanthoma elasticum (PXE)" refers to a progressive disorder characterized by the accumulation of calcium and other mineral deposits (calcification) in elastic fibers. Elastic fibers are components of connective tissue and provide strength and flexibility to structures throughout the body. In PXE, calcification affects the elastic fibers of the skin, eyes, and blood vessels, and less frequently in other areas such as the digestive tract. Patients with PXE may have yellowish bumps called papules on the neck, underarms, and other areas of the skin that touch when joints are bent. Calcification of the blood vessels (arteries) that carry blood from the heart to the rest of the body may cause other signs and symptoms of PXE. For example, people with this condition may develop a condition called claudication, which is characterized by muscle cramps and pain during exercise due to narrowing of the arteries (arteriosclerosis) or reduced blood flow to the arms and legs.

[0145] Pseudoxanthoma elasticum (PXE), also known as Glenn-Blood-Strandberry syndrome, is an inherited disorder that causes the breakage and calcification of elastic fibers in some tissues. The most common problems occur in the skin and eyes, and later in the blood vessels, in the form of premature atherosclerosis. PXE is caused by an autosomal recessive mutation in the ABCC6 gene (16p13.1) on the short arm of chromosome 16. In some cases, some infants survive GACI and develop pseudoxanthoma elasticum (PXE) when they grow into adults. PXE is characterized by the accumulation of calcium and other minerals (calcification) in elastic fibers, which are components of connective tissue. Connective tissue provides strength and flexibility to structures throughout the body. Features of PXE, which also occurs in GACI, include yellowish bumps called papules in the armpits and other areas of the skin that come into contact when bending joints (in flexion areas), narrowing of arteries, and abnormalities called pigmented streaks (retinal hemorrhages) that affect the tissue behind the eye that can be detected during an eye exam.

[0146] As used herein, the term "end stage renal disease (ESRD)" refers to an advanced stage of chronic kidney disease in which a patient's kidneys are no longer functioning. Common symptoms include fatigue, loss of appetite, nausea, vomiting, laboratory abnormalities including elevated potassium associated with anemia (low blood iron), hormonal abnormalities associated with bone health, elevated phosphorus and / or low calcium, high blood pressure (hypertension), swelling of the hands / legs / eyes / lower back (sacrum), and shortness of breath.

[0147] As used herein, "calcific uremic arteriopathy (CUA)" or "calciphylaxis" refers to a condition with high morbidity and mortality seen in patients with kidney disease, particularly end-stage renal disease (ESRD). It is characterized by calcification of small blood vessels located in fatty tissue and deep layers of the skin, which leads to blood clots, and death of skin cells due to reduced blood flow caused by excessive calcification.

[0148] As used herein, "hypophosphatemic rickets" refers to a disorder in which bones become soft and easily bent due to low phosphate levels in the blood. Symptoms usually begin in early childhood and vary in severity, including bowed legs, bone deformities, bone pain, joint pain, poor bone growth, and short stature.

[0149] As used herein, "hereditary hypophosphatemic rickets" refers to a disorder associated with low levels of phosphate in the blood (hypophosphatemia). Phosphate is an essential mineral for the normal formation of bones and teeth. It is most commonly caused by a mutation in the PHEX gene. Other genes that may cause the condition include the CLCN5, DMP1, ENPP1, FGF23, and SLC34A3 genes. Other signs and symptoms of hereditary hypophosphatemic rickets may include early fusion of the skull bones (craniosynostosis) and dental abnormalities. The disorder may also cause abnormal bone growth where ligaments and tendons attach to joints (enthesopathy). In adults, hypophosphatemia is characterized by softening of the bones, known as osteomalacia. Another rare type of disorder is known as hereditary hypophosphatemic rickets with hypercalciuria (HHRH), and in addition to hypophosphatemia, the condition is characterized by excretion of high levels of calcium in the urine (hypercalciuria).

[0150] As used herein, the term "X-linked hypophosphatemia (XLH)", X-linked hypophosphatemia (XLH), also referred to as X-linked dominant hypophosphatemic rickets, or X-linked vitamin D-resistant rickets, is an X-linked dominant form of rickets (or osteomalacia) that differs from most cases of rickets in that vitamin D supplementation does not cure it. It can cause bone deformities, including short stature and genu varum (bow legs). It is associated with a mutation in the PHEX gene sequence (Xp.22) and subsequent inactivity of the PHEX protein.

[0151] As used herein, the term "autosomal recessive hypophosphatemic rickets type 2 (ARHR2)" refers to an inherited renal phosphate-wasting disorder characterized by hypophosphatemia, rickets, and / or osteomalacia and growth retardation. Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) is caused by homozygous loss-of-function mutations in the ENPP1 gene.

[0152] As used herein, "autosomal dominant hypophosphatemic rickets (ADHR)" refers to a rare genetic disease in which excessive loss of phosphate in the urine leads to poorly formed bones (rickets), bone pain, and dental abscesses. ADHR is caused by mutations in fibroblast growth factor 23 (FGF23). ADHR is characterized by impaired bone mineralization, rickets and / or osteomalacia, suppressed levels of calcitriol (1,25-dihydroxyvitamin D3), renal phosphate wasting, and low serum phosphate. Mutations in FGF23 render the protein more stable and uncleavable by proteases, resulting in enhanced biological activity of FGF23. Enhanced activity of FGF23 mutants reduces expression of sodium phosphate cotransporters NPT2a and NPT2c on the apical surface of proximal tubule cells, resulting in renal phosphate wasting.

[0153] Hypophosphatemic rickets (previously called vitamin D-resistant rickets) is a disorder in which low levels of phosphate in the blood cause bones to become painfully soft and prone to bending. Symptoms can include bowed deformities of the legs and other bones, bone pain, joint pain, poor bone growth, and short stature. In some affected infants, the spaces between the skull bones close too early, leading to craniosynostosis. Most patients present with abnormalities of calcium-phosphate metabolism, abnormalities of dental enamel, delayed tooth eruption, and a long, narrow head (dolichocephaly).

[0154] As used herein, "pre-treatment" means treatment prior to the initiation of the treatment methods described herein.

[0155] As used herein, the term "PCSK9 inhibitor" refers to an inhibitor that blocks the PCSK9 enzyme. Proprotein convertase subtilisin / kexin type 9 (PCSK9) is an enzyme that binds to the low-density lipoprotein receptor (LDL receptor), which stops LDL from being removed from the blood, leading to increased blood levels of LDL. PCSK9 inhibitors block the PCSK9 enzyme, resulting in more LDL receptors being available to remove LDL from the blood, thereby resulting in lower LDL blood levels. Commonly known PCSK9 inhibitors include, but are not limited to, Repatha (evolocumab), Praulent (alirocumab). See "PCSK9 inhibitors: A new era of lipid lowering therapy", Chaudhary et al., World J Cardiol. 2017 Feb 26; 9(2): 76-91.

[0156] As used herein, the term "statin" refers to a class of lipid-lowering drugs that reduce disease and mortality in people at high risk of cardiovascular disease. They reduce the level of cholesterol in the blood by reducing the production of cholesterol by the liver. Commonly known examples of statins include, but are not limited to, atorvastatin (Lipitor), lovastatin (Altotref), pitavastatin (Livalo, Dipitamag), pravastatin (Pravachol), rosuvastatin (Crestor, Ezarol), and simvastatin (Zocor).

[0157] As used herein, "malignant" refers to the presence of cancer cells that have the ability to spread (metastasize) to other sites in the body or invade nearby (locally) and destroy tissue. Malignant cells tend to have rapid, uncontrolled growth and do not die normally due to changes in their genetic makeup. There are several main types of malignant tumors. Carcinomas are malignant tumors that begin in the skin or tissues that line or cover internal organs. Sarcomas are malignant tumors that begin in bone, cartilage, fat, muscle, blood vessels, or other connective or supporting tissues. Leukemias are malignant tumors that begin in blood-forming tissues, such as the bone marrow, and cause the body to make too many abnormal blood cells. Lymphomas and multiple myelomas are malignant tumors that begin in cells of the immune system. Central nervous system cancers are malignant tumors that begin in tissues of the brain and spinal cord.

[0158] As used herein, "non-melanoma skin cancer" refers to any cancer that forms in the basal, squamous, or Merkel cells of the skin. Melanoma is a cancer that develops in the melanocytes of the skin.

[0159] As used herein, "sponsor of a clinical trial" means a person, institution, company, or organization (e.g., a contract research organization) that is responsible for initiating, managing, or funding a clinical trial, but does not actually conduct the study.

[0160] As used herein, the term "subject" refers to an individual, such as a mammal, such as a human, a non-human primate (e.g., chimpanzees and other hominoids and monkey species), a farm animal (e.g., birds, fish, cows, sheep, pigs, goats, and horses), a domestic mammal (e.g., dogs and cats), or a laboratory animal (e.g., rodents, such as mice, mice, and guinea pigs). The term includes subjects of any age or sex. In another embodiment, the subject is a mammal, preferably a human.

[0161] A disease or disorder is "alleviated" if the severity of a symptom of the disease or disorder, the frequency with which such symptoms are experienced by a patient, or both, are reduced.

[0162] As used herein, the terms "alteration," "defect," "variation," or "mutation" refer to a mutation in a gene in a cell that affects the function, activity, expression (transcription or translation) or conformation of the polypeptide it encodes, including missense and nonsense mutations, insertions, deletions, frameshifts, and premature terminations.

[0163] A "disease" is a condition in the health of an animal in which the animal is unable to maintain homeostasis, and if the disease is not ameliorated, the animal's health will continue to deteriorate.

[0164] A "disorder" in an animal is a state of health in which the animal is able to maintain homeostasis but in which the animal's health is less favorable than it would be in the absence of the disorder. If left untreated, the disorder does not necessarily cause a further deterioration in the animal's health.

[0165] As used herein, the term "immune response" or "immune reaction" refers to the host's immune system responding to an antigen in an invading (infectious) pathogenic organism or to the introduction or expression of a foreign protein. Immune responses are generally humoral and localized, with antibodies produced by B cells combining with the antigen in an antigen-antibody complex to inactivate or neutralize the antigen. When human proteins are injected into mouse model systems, immune responses are often observed. Generally, mouse model systems are made immune tolerant by injecting immunosuppressants prior to the introduction of foreign antigens to ensure better survival rates.

[0166] As used herein, the term "immunosuppression" is the intentional reduction in the activation or effectiveness of the host immune system using immunosuppressants to promote immune tolerance to foreign antigens, such as foreign proteins, organ transplants, bone marrow and tissue transplants, etc. Non-limiting examples of immunosuppressants include anti-CD4 (GK1.5) antibodies, cyclophosphamide, azathioprine (Imuran), mycophenolate mofetil (Cellcept), cyclosporine (Neoral, Sandimmune, Gengraf), methotrexate (Rheumatrex), leflunomide (Arava), cyclophosphamide (Cytoxan), and chlorambucil (Leukeran).

[0167] As used herein, the term "ENPP" or "NPP" refers to ectonucleotide pyrophosphatase / phosphodiesterase.

[0168] As used herein, the term "ENPP1 protein" or "ENPP1 polypeptide" refers to the ectonucleotide pyrophosphatase / phosphodiesterase-1 protein encoded by the ENPP1 gene. The encoded protein is a type II transmembrane glycoprotein that cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars, and pyrophosphate bonds of nucleotides and nucleotide sugars. The ENPP1 protein has a transmembrane domain and a soluble extracellular domain. The extracellular domain is further subdivided into a somatomedin B domain, a catalytic domain (residues 186-586 of SEQ ID NO:1), and a nuclease domain (residues 524-885 of SEQ ID NO:1). The sequence and structure of wild-type ENPP1 are described in detail in PCT Publication No. 2014 / 126965 to Braddock, et al., which is incorporated herein by reference in its entirety.

[0169] Mammalian ENPP1 polypeptides, variants, or variant fragments thereof have been previously disclosed in International PCT Publication Nos. 2014 / 126965 - Braddock et al., 2016 / 187408 - Braddock et al., 2017 / 087936 - Braddock et al., and 2018 / 027024 - Braddock et al., all of which are incorporated by reference in their entireties herein.

[0170] As used herein, the term "ENPP1 precursor protein" refers to ENPP1 having its signal peptide sequence at the ENPP1 N-terminus. Upon proteolysis, the signal sequence is cleaved from ENPP1 to provide the ENPP1 protein. Signal peptide sequences useful within the present invention include, but are not limited to, the albumin signal sequence, the azurocidin signal sequence, the ENPP1 signal peptide sequence, the ENPP2 signal peptide sequence, the ENPP7 signal peptide sequence, and / or the ENPP5 signal peptide sequence.

[0171] As used herein, the term "ENPP1-Fc construct" refers to ENPP1 recombinantly fused and / or chemically conjugated (including both covalent and non-covalent binding) to an FcR binding domain of an IgG molecule (preferably human IgG). In certain embodiments, the C-terminus of ENPP1 is fused or conjugated to the N-terminus of the FcR binding domain.

[0172] As used herein, the term "Fc" refers to the human IgG (immunoglobulin) Fc domain. Subtypes of IgG, such as IgG1, IgG2, IgG3, and IgG4, are contemplated for use as the Fc domain.

[0173] As used herein, "Fc region or Fc polypeptide" is the portion of an IgG molecule that correlates with the crystallizable fragment obtained by papain digestion of the IgG molecule. The Fc region comprises the C-terminal halves of the two heavy chains of an IgG molecule that are linked by disulfide bonds. It lacks antigen binding activity, but contains the carbohydrate moiety and binding sites of complement and Fc receptors, including the FcRn receptor. The Fc fragment comprises the entire second constant domain CH2 (residues 231-340 of human IgG1 according to the Kabat numbering system) and the third constant domain CH3 (residues 341-447). The term "IgG hinge-Fc region" or "hinge-Fc fragment" refers to the region of an IgG molecule that consists of the Fc region (residues 231-447) and the hinge region (residues 216-230) that extends from the N-terminus of the Fc region. The term "constant domain" refers to the portion of an immunoglobulin molecule that has a more conserved amino acid sequence relative to the other portions of the immunoglobulin, the variable domains, including the antigen binding sites. Constant domains include the CH1, CH2, and CH3 domains of the heavy chain and the CHL domain of the light chain.

[0174] As used herein, when applied to nucleic acids, the term "fragment" refers to a subsequence of a larger nucleic acid. A "fragment" of a nucleic acid can be at least about 15, 50-100, 100-500, 500-1000, 1000-1500 nucleotides, 1500-2500, or 2500 nucleotides (and any integer value in between). As used herein, when applied to a protein or peptide, the term "fragment" refers to a subsequence of a larger protein or peptide and can be at least about 20, 50, 100, 200, 300, or 400 amino acids in length (and any integer value in between).

[0175] "Isolated" means altered or removed from the natural state. For example, a nucleic acid or polypeptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or polypeptide that has been partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in a substantially purified form, or can exist in a non-native environment, such as, for example, a host cell.

[0176] As used herein, the terms "patient," "individual," or "subject" refer to a human.

[0177] As used herein, the term "pharmaceutical composition" or "composition" refers to a mixture of at least one compound useful within the present invention with a pharma- ceutical acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient. Multiple techniques of administering the compound exist in the art, including, but not limited to, subcutaneous, intravenous, oral, aerosol, inhalation, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastric, ocular, pulmonary, and topical administration.

[0178] As used herein, the term "pharmaceutical acceptable" refers to a material, such as a carrier or diluent, that does not destroy the biological activity or properties of the compound and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesired biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained, such as, for example, phosphate buffered saline (PBS).

[0179] As used herein, the term "plasma pyrophosphate (PPi) level" refers to the amount of pyrophosphate present in the plasma of an animal. In certain embodiments, the animals include rats, mice, cats, dogs, humans, cows, and horses. Due to release from platelets, it is necessary to measure PPi in plasma rather than serum. There are several ways to measure PPi, one of which is by an enzyme assay using uridine-diphosphoglucose (UDPG) pyrophosphorylase with modification (Lust & Seegmiller, 1976, Clin. Chim. Acta 66:241-249; Cheung & Suhadolnik, 1977, Anal. Biochem. 83:61-63). Typically, normal PPi levels in healthy subjects range from about 1 μM to about 3 μM, and in some cases, 1-2 μM. Subjects with ENPP1 expression deficiency tend to exhibit low PPi levels ranging from at least 10% below normal, at least 20% below normal, at least 30% below normal, at least 40% below normal, at least 50% below normal, at least 60% below normal, at least 70% below normal, at least 80% below normal, and combinations thereof. In patients afflicted with GACI, PPi levels are found to be below 1 μm, and in some cases below detectable levels. In patients afflicted with PXE, PPi levels are below 0.5 μm. (Arterioscler Thromb Vasc Biol. 2014 Sep; 34(9): 1985-9, Braddock et al., Nat Commun. 2015; 6: 10006.)

[0180] As used herein, the term "polypeptide" refers to a polymer composed of amino acid residues associated with naturally occurring structural variants, and synthetic, non-naturally occurring analogues thereof, linked through peptide bonds.

[0181] As used herein, the term "PPi" refers to pyrophosphate.

[0182] As used herein, the term "prevent" or "prevention" refers to the absence of onset of a disorder or disease when none would have occurred, or the absence of further development of a disorder or disease when onset of a disorder or disease is already present. Also contemplated is the ability to prevent some or all of the symptoms associated with a disorder or disease.

[0183] As used herein, "sample" or "biological sample" refers to biological material isolated from a subject. A biological sample may include any biological material suitable for detection of mRNA, polypeptides, or other markers of physiological or pathological processes in a subject, and may include fluids, tissues, cells, and / or non-cellular material obtained from an individual.

[0184] As used herein, "substantially purified" refers to being essentially free of other components. For example, a substantially purified polypeptide is one that has been separated from other components with which it is normally associated in its naturally occurring state. Non-limiting embodiments include 95% purity, 99% purity, 99.5% purity, 99.9% purity, and 100% purity.

[0185] As used herein, the term "treatment" or "treating" is defined as the application or administration of a therapeutic agent, i.e., a compound useful in the present invention (alone or in combination with another pharmaceutical agent), to a patient, or to an isolated tissue or cell line (e.g., for diagnostic or ex vivo applications) from a patient having a disease or disorder, a symptom of a disease or disorder, or the potential for developing a disease or disorder, with the purpose of curing, curing, mitigating, alleviating, altering, correcting, ameliorating, improving, or affecting the disease or disorder, the symptom of a disease or disorder, or the potential for developing a disease or disorder. Such treatments may be specifically tailored or modified based on knowledge gained from the field of pharmacogenomics.

[0186] As used herein, the terms "prevent", "preventing" and "prevention" refer to the inhibition of onset or reduction in occurrence of a disease in a subject. Prevention may be complete (e.g., the complete absence of pathological cells in a subject) or may be partial. Prevention also refers to a reduction in susceptibility to a clinical condition.

[0187] As used herein, the term "wild type" refers to a gene or gene product isolated from a naturally occurring source. A wild type gene is the one most frequently observed in a population and is therefore arbitrarily designated the "normal" or "wild type" form of the human NPP1 gene. In contrast, the term "functional equivalent" refers to an NPP1 gene or gene product that exhibits modified sequence and / or functional properties (i.e., altered properties) when compared to the wild type gene or gene product. Naturally occurring mutants can be isolated. They are identified by the fact that they have altered characteristics (including altered nucleic acid sequences) when compared to the wild type gene or gene product.

[0188] As used herein, the term "functionally equivalent variant" refers to a polypeptide that is substantially homologous to the sequence of ENPP1 (as defined above) and retains the enzymatic and biological activity of ENPP1. Methods for determining whether a variant retains the biological activity of native ENPP1 are well known to those skilled in the art and include any of the assays used in the experimental part of the application. In particular, functionally equivalent variants of ENPP1 delivered by viral vectors are encompassed by the present invention.

[0189] A functionally equivalent variant of ENPP1 is a polypeptide that is substantially homologous to the naturally occurring ENPP1. The term "substantially homologous" relates to a protein sequence when said protein sequence has a degree of identity of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% with respect to the ENPP1 sequences listed above, respectively.

[0190] The degree of identity between two polypeptides is determined using computer algorithms and methods well known to those skilled in the art. The identity between two amino acid sequences is preferably determined by using the BLASTP algorithm (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894, Altschul, S., et al. J. Mol. Biol. 215: 403-410 (1990)), although other similar algorithms can also be used. BLAST and BLAST 2.0 are used to determine percent sequence identity using the parameters described herein. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information.

[0191] "Functionally equivalent variants" of ENPP1 can be obtained by replacing nucleotides in a polynucleotide that describes the codon preferences in the host cell used to produce ENPP1, respectively. Such "codon optimization" can be determined via a computer algorithm that incorporates a codon frequency table, such as "Human high.cod" of codon preferences provided by the University of Wisconsin Package Version 9.0, Genetics Computer Group, Madison, Wis.

[0192] As used herein when referring to a measurable value, such as an amount, duration, and the like, "about" is meant to encompass variations of ±10% or ±5%, in certain embodiments ±1-5%, in certain embodiments ±5%, in certain embodiments ±4%, in certain embodiments ±4%, in certain embodiments ±3%, in certain embodiments ±2%, and in certain embodiments ±1% from the specified value (0.2 mg / kg or 0.6 mg / kg or 1.8 mg / kg), as such variations are appropriate for carrying out the disclosed methods.

[0193] This disclosure provides representative examples of protein sequences. The described protein sequences can be converted to nucleic acid sequences by performing revere translation and codon optimization. Expasy ( https: / / www.expasy.org / There are several tools available in the art, such as the Bioinformatics Library (http: / / www.bioinformatics.org) and Bioinformatics Server (http: / / www.bioinformatics.org).

[0194] Ranges: Throughout this disclosure, various aspects according to the present invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation according to the present invention. Thus, the description of a range should be considered to have specifically disclosed all possible subranges as well as individual numerical values ​​within that range. For example, a description of a range such as 1-6 should be considered to have specifically disclosed subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, and individual numbers within that range such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

[0195] Preferred methods and materials are described herein, although methods and materials similar or equivalent to those disclosed herein can also be used in the practice or testing of the disclosed methods and compositions. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0196] ABCC6 mutation detection Genomic DNA is isolated from peripheral blood samples of subjects suspected of having ABC66 deficiency using a commercially available DNA isolation kit (Puregene DNA Isolation Kit, Gentra Systems, Minneapolis, Minnesota, USA). Control genomic DNA is obtained from human lymphoblastoid cell line K562 (American Type Culture Collection, Manassas, Virginia, USA). All DNA samples are adjusted to a concentration of 10 ng / uL in water.

[0197] The mutation detection strategy was based on: (1) identification of the recurrent mutations R1141X and del23-29 by restriction enzyme digestion, (2) optimized denaturing high-performance liquid chromatography (dHPLC) scanning of PCR products corresponding to all exons in subjects in which the two recurrent mutations were not identified on both alleles, followed by (3) sequencing of exons with altered dHPLC patterns, and (4) confirmation of novel mutations by restriction enzyme digestion or resequencing.

[0198] Screening for recurrent mutations R1141X and del23-29 is performed as described previously. (Compound heterozygosity for a recurrent 16.5-kb Alu-mediated deletion mutation and single base pair substitution in the ABCC6 gene results in pseudoxanthoma elasticum. Ringpfeil F, Nakano A, Uitto J, Pulkkinen L, Am J Hum Genet. 2001 Mar;68(3):642-52.) Conditions and primers to generate PCR products spanning all exons and adjacent intronic sequences of the coding region of the ABCC6 gene are specified in the supplementary table for optimal dHPLC screening (J Med Genet. 2007 Oct;44(10):621-628.).

[0199] These primers are designed to exclude pseudogenes homologous to exons 1-4 and 1-931, anneal within approximately 50 bases of the 5' and 3' ends of exons, and exclude known intronic polymorphisms, if possible. PCR for dHPLC analysis is performed using 5 U of Optimase Taq polymerase (Transgenomic, Gaithersburg, Maryland, USA) and 1.5 U of Taq polymerase (Qiagen Inc., Valencia, California, USA) mixed with Q buffer (Qiagen) according to the manufacturer's instructions. PCR reactions contained 200 ng of DNA as template and 20 ng of each primer in a final volume of 50 ul. Cycling conditions for all primer pairs were 94°C for 5 min, followed by 41 cycles of 94°C for 1 min, annealing temperature of the specific primer pair (range 55-60°C) for 1 min, and 72°C for 1 min, with a final step of 72°C for 5 min.

[0200] PCR products generated using patients with PXE DNA as template can form heteroduplexes with equal volumes of PCR products of the same exons amplified from template DNA of lymphoblastoid control cell line K562. For this purpose, PCR products are mixed in a 1:1 ratio and denatured at 94°C for 10 min, followed by reannealing at 65°C for 15 min and 37°C for 15 min. PCR products are then screened by dHPLC (WAVE; Transgenomic, Gaithersburg, Maryland, USA) using a method designed to enhance partial denaturation of PCR products containing mismatched bases (see Supplementary Table 1 in J Med Genet. 2007 Oct; 44(10):621-628). PCR products that show pattern shifts are most often sequenced in both directions. DNA sequencing is performed on an automated sequencer (ABI Prism 377 or ABI 3100; Perkin-Elmer-Cetus, Foster City, California, USA). Putative mutations are confirmed by restriction enzyme digestion followed by agarose gel electrophoresis, or by resequencing of the new PCR products if suitable restriction enzymes are not available. Subjects are then identified as having an ABCC6 mutation if they are found to contain a known mutation in the ABCC6 gene that affects the activity and / or expression level of the ABCC6 protein.

[0201] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 1. Overview The present disclosure provides for treating, preventing, or reducing the rate of progression and / or severity of pathological calcification and / or ossification, or one or more complications of pathological calcification and / or ossification, by subcutaneously (SC) administration of ENPP1-FC to a subject at a dose of about 0.2 mg / kg, about 0.6 mg / kg, or about 1.8 mg / kg. With reference to the recited doses of ENPP1-FC, "about" means a degree of error assuming the nature or precision of the measurements within ±5 percent (%), ±4%, ±3%, or ±2%, or ±1% of the recited dose in mg of ENPP1-FC / kg body weight of the subject.

[0202] 2. Dosage of ENPP1 drug The ENPP1 agent is administered at a dose of about 0.2 mg / kg, about 0.6 mg / kg, or about 1.8 mg / kg. A medical professional may select which of these doses is administered to a given subject, guided by the subject's serum PPi level, and the selected dose is sufficient to restore the subject's PPi to normal levels.

[0203] 3. ENPP1 drugs The ENPP1 agent is an ENPP1 polypeptide. The ENPP1 polypeptide disclosed herein includes naturally occurring polypeptides of the ENPP1 family and any variants thereof (including mutants, fragments, fusions, and / or peptidomimetic forms) that retain biological activity. The term "ENPP1" or "ENPP1 polypeptide" refers to ectonucleotide pyrophosphatase / phosphodiesterase 1 protein (NPP1 / ENPP1 / PC-1) and ENPP1-related proteins from any species. ENPP1 proteins include type II transmembrane glycoproteins that form homodimers. Each monomer of ENPP1 protein includes a short intracellular N-terminal domain involved in targeting to the plasma membrane, a transmembrane domain, and a large extracellular region that includes several domains. The large extracellular region includes the SMB1 and SMB2 domains, which have been reported to be involved in ENPP1 dimerization (R. Gijsbers, H. et al., Biochem. J. 371; 2003: 321-330). Specifically, the SMB domain contains eight cysteine ​​residues, each arranged in four disulfide bonds, and has been shown to mediate ENPP1 homodimerization through covalent intercystine and intramolecular bonds. The protein cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars, and pyrophosphate bonds of nucleotides and nucleotide sugars. The ENPP1 protein functions to hydrolyze nucleoside 5' triphosphatases to the corresponding monophosphates, and also hydrolyze diadenosine polyphosphates. The ENPP1 protein plays a role in purinergic signaling, which is involved in regulating cardiovascular, neurological, immunological, musculoskeletal, hormonal, and hematological functions. An exemplary amino acid sequence of human ENPP1 precursor protein (NCBI accession NP_006199) is shown in FIG. 2 (SEQ ID NO: 1). Human ENPP1 precursor protein contains an endogenous ENPP1 signal peptide sequence at the ENPP1 N-terminus. Amino acid numbering for all ENPP1-related polypeptides described herein is based on the numbering of the human ENPP1 precursor protein sequence provided in FIG. 2, unless otherwise specified.In certain embodiments, the ENPP1 precursor protein further comprises an endogenous or heterologous signal peptide sequence. During proteolysis, the signal peptide sequence is cleaved from the ENPP1 precursor protein to provide the mature ENPP1 protein. See, for example, Jansen S, et al. J Cell Sci. 2005; 118 (Pt 14): 3081-9. Exemplary signal peptide sequences that may be used with the polypeptides disclosed herein include, but are not limited to, the ENPP1 signal peptide sequence, the ENPP2 signal peptide sequence, the ENPP7 signal peptide sequence, and / or the ENPP5 signal peptide sequence. The processed (mature) extracellular ENPP1 polypeptide sequence is shown in Figure 4 (SEQ ID NO: 2).

[0204] In general, it is known in the art that ENPP1 is well conserved among vertebrates, and most of the extracellular domain is substantially conserved. For example, Figure 5A and Figure 5B illustrate multiple alignments of human ENPP1 extracellular domain compared to various ENPP1 orthologs. ENPP1, which binds various nucleotide triphosphates (e.g., ATP, UTP, GTP, TTP, and CTP), pNP-TMP, 3',5'-cAMP, and 2'-3'-cGAMP, is also highly conserved (see, for example, Kato K. et al., Proc Natl Acad Sci USA. 2012; 109(42): 16876-81 and Mackenzie NC, et al. Bone. 2012; 51(5): 961-8). Thus, from these alignments, it is possible to predict important amino acid positions with the extracellular domain that are important for normal ENPP1 activity, and to predict amino acid positions that are likely to tolerate substitution without significantly altering normal ENPP1 activity. Thus, active human ENPP1 polypeptides useful according to the methods of the present disclosure may contain one or more amino acids at the corresponding positions from the sequence of another vertebrate ENPP1, or may contain similar residues to those of the human or other vertebrate sequence. Substitution of one or more amino acids at the corresponding positions may include conservative variations or substitutions that are unlikely to alter the shape of the polypeptide chain or alter normal ENPP1 activity. Examples of conservative variations or substitutions include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine, or methionine, for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamine for aspartic acid, or glutamine for asparagine. For example, ENPP1 polypeptides include polypeptides derived from the sequence of any known ENPP1 polypeptide having a sequence identity of at least about 80%, preferably at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, to the sequence of an ENPP1 polypeptide.

[0205] 4.Enzyme activity of ENPP1 ENPP1 proteins have been characterized in the art in terms of structural and biological features. In certain embodiments, the soluble ENPP1 proteins disclosed herein comprise pyrophosphatase and / or phosphodiesterase activity. For example, in some embodiments, the ENPP1 protein binds nucleotide triphosphates (e.g., ATP, UTP, GTP, TTP, and CTP), pNP-TMP, 3',5'-cAMP, and 2'-3'-cGAMP and converts the nucleotide triphosphates to inorganic pyrophosphates [see, e.g., Kato K. et al., Proc Natl Acad Sci USA. 2012; 109(42): 16876-81, Li L, et al. Nat Chem Biol. 2014; 10(12): 1043-8, Jansen S, et al. Structure. 2012; 20(11): 1948-59, and Onyedibe KI, et al. Molecules. 2019; 24(22)].

[0206] "Enzymatically active" or "biologically active" refers to an ENPP1 polypeptide that exhibits pyrophosphatase and / or phosphodiesterase activity (e.g., can bind and / or hydrolyze ATP to AMP and PPi, and / or AP3a to ATP). For example, the pyrophosphatase / phosphodiesterase domain of the ENPP1 protein hydrolyzes extracellular nucleotide triphosphates to generate inorganic pyrophosphate (PPi) and is generally soluble. This activity can be measured using a pNP-TMP assay as previously described (Saunders, et al., 2008, Mol. Cancer Ther. 7(10):3352-62; Albright, et al., 2015, Nat Comm. 6:10006). In certain embodiments, a soluble ENPP1 polypeptide has a pyrophosphatase activity of about 3.4 (±0.4) s ’1 enzyme ’1 k for the substrate ATP cat has a value k catis determined by measuring the rate of hydrolysis of ATP for the polypeptide. In certain embodiments, the soluble ENPP1 polypeptide has a K for the substrate ATP of about 2 μM or less. M has a value of K M is determined by measuring the rate of ATP hydrolysis for the polypeptide. In addition to the teachings herein, these references provide ample guidance for methods to generate soluble ENPP1 proteins that retain one or more biological activities (e.g., conversion of nucleotides to inorganic pyrophosphate).

[0207] 5.Soluble ENPP1 In one embodiment, the present disclosure relates to an ENPP1 polypeptide. As described herein, the term soluble ENPP1 polypeptide includes any naturally occurring extracellular domain of the ENPP1 protein, and any variants thereof (including mutants, fragments, and peptidomimetic forms) that retain biological activity (e.g., enzymatic activity). An example of a soluble ENPP1 polypeptide includes, for example, the ENPP1 extracellular domain (SEQ ID NO: 2), as shown in FIG. 4. In certain embodiments, the soluble ENPP1 polypeptide further includes a signal sequence in addition to the extracellular domain of the ENPP1 polypeptide. Exemplary signal sequences include the native signal sequence of the ENPP1 polypeptide, or a signal sequence from another protein, such as the hENPP7 signal sequence. Examples of variant soluble ENPP1 polypeptides are provided in International Patent Application Publication Nos. 2012 / 125182, 2014 / 126965, 2016 / 187408, 2018 / 027024, 2020206302, and 2020 / 047520, all of which are incorporated by reference in their entireties.

[0208] 6. ENPP1 fusion protein In some embodiments, the ENPP1 polypeptide is a fusion protein comprising an ENPP1 polypeptide domain and one or more heterologous protein moieties (i.e., polypeptide domains heterologous to ENPP1). An amino acid sequence is understood to be heterologous to ENPP1 if it is not uniquely found in the form of ENPP1 represented by SEQ ID NO:1. In some embodiments, the heterologous protein moiety comprises an immunoglobulin Fc domain. In some embodiments, the immunoglobulin Fc domain is an IgG1 immunoglobulin Fc domain. In certain embodiments, the soluble ENPP1 polypeptide is C-terminally fused to an Fc domain of human immunoglobulin 1 (IgG1), human immunoglobulin 2 (IgG2), human immunoglobulin 3 (IgG3), and / or human immunoglobulin 4 (IgG4). In other embodiments, the soluble ENPP1 polypeptide is N-terminally fused to an Fc domain of human immunoglobulin 1 (IgG1), human immunoglobulin 2 (IgG2), human immunoglobulin 3 (IgG3), and / or human immunoglobulin 4 (IgG4). In some embodiments, the presence of an Fc domain improves the half-life, solubility, reduces immunogenicity, and increases activity of soluble ENPP1 polypeptides. In certain embodiments, a portion of a native human IgG protein (IgG1, IgG2, IgG3, and IgG4) may be used in place of the Fc portion (e.g., ENPP1-Fc). For example, the present disclosure provides a fusion protein comprising ENPP1 fused to a polypeptide comprising an immunoglobulin constant domain, such as a CH1, CH2, or CH3 domain from human IgG1, IgG2, IgG3, and / or IgG4. The Fc fragment may include a region of a native IgG, such as the hinge region (residues 216-230 of human IgG1 according to the Rabat numbering system), the entire second constant domain CH2 (residues 231-340), and the third constant domain CH3 (residues 341-447). As used herein, the term "ENPP1-Fc construct" refers to a soluble form of ENPP1 (e.g., the extracellular domain of ENPP1) recombinantly fused and / or chemically conjugated (including both covalent and non-covalent binding) to the FcR binding domain of an IgG molecule (preferably human IgG).In certain embodiments, the C-terminus of ENPP1 is fused or conjugated to the N-terminus of the FcR binding domain.

[0209] An example of an amino acid sequence that can be used for the Fc portion of human IgG1 (G1Fc) is SEQ ID NO: 6 (Table 1). In part, the disclosure provides polypeptides comprising, consisting essentially of, or consisting of an amino acid sequence having 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:6.

[0210] In some embodiments, the heterologous protein portion comprises one or more domains selected from the group consisting of polyhistidine, FLAG tag, Glu-Glu, glutathione S-transferase (GST), thioredoxin, protein A, protein G, immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), or human serum albumin. The fusion domain may be selected to confer desired properties. For example, some fusion domains are particularly useful for the isolation of fusion proteins by affinity chromatography. For affinity purification purposes, relevant substrates for affinity chromatography are used, such as glutathione, amylase, and nickel or cobalt conjugated resins. Many such substrates are available in "kit" form, such as the QIAexpress™ system (Qiagen) useful with the Pharmacia GST purification system and (HIS6) fusion partners. As another example, the fusion domain may be selected to facilitate detection of the ENPP1 polypeptide. Examples of such detection domains include various fluorescent proteins (e.g., GFP) and "epitope tags," which are usually short peptide sequences for which specific antibodies are available. Well-known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus hemagglutinin (HA), and c-myc tags. In some cases, the fusion domain has a protease cleavage site, e.g., factor Xa or thrombin, which allows the relevant protease to partially digest the fusion protein, thereby releasing the recombinant protein therefrom. The released protein can then be isolated from the fusion domain by subsequent chromatographic separation.

[0211] 7. Linker In some embodiments, the ENPP1 fusion protein further comprises a linker positioned between the ENPP1 polypeptide domain and one or more heterologous protein moieties (e.g., Fc immunoglobulin domains). In certain embodiments, the soluble ENPP1 polypeptide is directly or indirectly fused to the Fc domain. In some embodiments, the soluble ENPP1 fusion protein comprises a linker between the Fc domain and the ENPP1 polypeptide. In some embodiments, the linker may be an amino acid spacer comprising 1-200 amino acids. Suitable peptide spacers are known in the art and include, for example, peptide linkers comprising flexible amino acid residues such as glycine, alanine, and serine. In some embodiments, the linker comprises a polyglycine linker or a Gly-Ser linker. In some embodiments, the spacer may include multiple or repeated motifs, for example, of GA (SEQ ID NO:21), GS (SEQ ID NO:22), GG (SEQ ID NO:23), GGA (SEQ ID NO:24), GGS (SEQ ID NO:25), GGG (SEQ ID NO:26), GGGA (SEQ ID NO:27), GGGS (SEQ ID NO:28), GGGG (SEQ ID NO:29), GGGGA (SEQ ID NO:30), GGGGS (SEQ ID NO:31), GGGGG (SEQ ID NO:32), GGAG (SEQ ID NO:33), GGSG (SEQ ID NO:34), AGGG (SEQ ID NO:35), SGGGG (SEQ ID NO:36), or SGGG (SEQ ID NO:37).In some embodiments, the spacer can include 2 to 12 amino acids containing a GA or GS motif, e.g., GA, GS, GAGA (SEQ ID NO:38), GSGS (SEQ ID NO:39), GAGAGA (SEQ ID NO:40), GSGSGS (SEQ ID NO:41), GAGAGAGA (SEQ ID NO:42), GSGSGSGS (SEQ ID NO:43), GAGAGAGAGA (SEQ ID NO:44), GSGSGSGSGS (SEQ ID NO:45), GAGAGAGAGAGA (SEQ ID NO:46), and GSGSGSGSGSGS (SEQ ID NO:47). In some embodiments, the spacer can include 3-12 amino acids containing the motifs GGA or GGS, e.g., GGA, GGS, GGAGGA (SEQ ID NO:48), GGSGGS (SEQ ID NO:49), GGAGGAGGA (SEQ ID NO:50), GGSGGSGGS (SEQ ID NO:51), GGAGGAGGAGGA (SEQ ID NO:52), and GGSGGSGGSGGS (SEQ ID NO:53). In further embodiments, the spacer can include 4-12 amino acids containing the motifs GGAG (SEQ ID NO:54), GGSG (SEQ ID NO:55), e.g., GGAG (SEQ ID NO:56), GGSG (SEQ ID NO:57), GGAGGGAG (SEQ ID NO:58), GGSGGGSG (SEQ ID NO:59), GGAGGGAGGGAG (SEQ ID NO:60), and GGSGGGSGGGSG (SEQ ID NO:61). In some embodiments, the spacer may include the motif GGGGA (SEQ ID NO: 62) or GGGGS (SEQ ID NO: 63), e.g., GGGAGGGGAGGGGA (SEQ ID NO: 64) and GGGGSGGGSGGGGGS (SEQ ID NO: 65).In some embodiments of the invention, the amino acid spacer between the heterologous protein moiety (e.g., an Fc domain monomer, a wild-type Fc domain, an Fc domain with amino acid substitutions (e.g., one or more substitutions that reduce dimerization), an albumin binding peptide, a fibronectin domain, or human serum albumin) and the soluble ENPP1 polypeptide can be GGG, GGGA (SEQ ID NO:27), GGGG (SEQ ID NO:29), GGGAG (SEQ ID NO:66), GGGAGG (SEQ ID NO:67), or GGGAGGG (SEQ ID NO:68).

[0212] In some embodiments, the spacer may also include amino acids other than glycine, alanine, and serine, such as, for example, .,LIN (SEQ ID NO:69), TGGGG (SEQ ID NO:70), AAL (SEQ ID NO:71), AAAK (SEQ ID NO:72), AAR (SEQ ID NO:73), EGKSSGSGSESKST (SEQ ID NO:74), GSAGSAAGSGEF (SEQ ID NO:75), AEAAAKEAAAKA (SEQ ID NO:76), KESGSVSEQLAQFRSLD (SEQ ID NO:77), GENLYFQSGG (SEQ ID NO:78), SACYCELS (SEQ ID NO:79), RSIAT (SEQ ID NO:80), RPACKIPNDLKQKVMNH (SEQ ID NO:81), GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG (SEQ ID NO:82), AAANSSIDLISVPVDSR (SEQ ID NO:83), . NO:83),GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS(SEQ ID NO:84),NSS(SEQ ID NO:87),ESS(SEQ ID NO:88),RQQ(SEQ ID NO:89),KR(SEQ ID NO:90),(R) m; m=0-15(SEQ ID NO:91),DSSSEEKFLRRIGRFG(SEQ ID NO:92),EEEEEEEPRGDT(SEQ ID NO:93),APWHLSSQYSRT(SEQ ID NO:94),STLPIPHEFSRE(SEQ ID NO:95),VTKHLNQISQSY(SEQ ID NO:96),(E) m ; m=1-15(SEQ ID NO:97),RSGSGGS(SEQ ID NO:98),(D) m ; m=1-15 (SEQ ID NO: 99), LVIMSLGLGLGLGLRK (SEQ ID NO: 100), VIMSLGLGLGLGLRK (SEQ ID NO: 101), IMSLGLGLGLGLRK (SEQ ID NO: 102), MSLGLGLGLGLRK (SEQ ID NO: 103), SLGLGLGLGLRK (SEQ ID NO: 104), LGLGLGLGLRK (SEQ ID NO: 105), GLGLGLGLRK (SEQ ID NO: 106), LGLGLGLRK (SEQ ID NO: 107), GLGLGLRK (SEQ ID NO: 108), LGLGLRK (SEQ ID NO: 109), GLGLRK (SEQ ID NO: 110), LGLRK (SEQ ID NO: 111), GLRK (SEQ ID NO: 112), LRK (SEQ ID NO: 113), RK (SEQ ID NO: 114), or (K) m ; m=1-15 (SEQ ID NO:115). In some embodiments, the spacer may include a motif, e.g., a multiple or repeated motif, of EAAAK (SEQ ID NO:85). In some embodiments, the spacer may include a motif, e.g., a multiple or repeated motif, of a praline-rich sequence, such as (XP)n, where X can be any amino acid (e.g., A, K, or E) and n is 1-5, and PAPAP (SEQ ID NO:86).

[0213] The length of the peptide spacer and the amino acids used can be adjusted depending on the two proteins involved and the degree of flexibility desired in the final protein fusion polypeptide. The length of the spacer can be adjusted to ensure proper protein folding and avoid aggregate formation.

[0214] In some embodiments, the different elements of a fusion protein (e.g., an immunoglobulin Fc fusion protein) may be arranged in any manner consistent with the desired functionality. For example, a soluble ENPP1 polypeptide domain may be arranged C-terminal to a heterologous protein portion, or alternatively, a heterologous protein portion may be arranged C-terminal to a soluble ENPP1 polypeptide domain. The soluble ENPP1 polypeptide domain and the heterologous protein portion may be directly or indirectly linked in a fusion protein, and additional domains or amino acid sequences may be included C- or N-terminal to either domain or between the domains. A preferred fusion protein comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 3-5.

[0215] In some embodiments, the soluble ENPP1 polypeptide of the present disclosure comprises one or more heterologous moieties. Optionally, the soluble ENPP1 polypeptide comprises one or more heterologous moieties selected from glycosylated amino acids, PEGylated amino acids, phamesylated amino acids, acetylated amino acids, biotinylated amino acids, amino acids conjugated to lipid moieties, and amino acids conjugated to organic derivatizing agents. In some embodiments, the soluble ENPP1 polypeptide disclosed herein is further modified. Such modifications include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. As a result, the soluble ENPP1 polypeptide may comprise non-amino acid elements, such as polyethylene glycol, lipids, polysaccharides or monosaccharides, and phosphates. The effect of such non-amino acid elements on the functionality of the soluble ENPP1 polypeptide may be tested as described herein for other soluble ENPP1 polypeptides. When the polypeptides of the present disclosure are produced intracellularly by cleaving the nascent form of the polypeptide, post-translational processing may also be important for correct folding and / or function of the protein. Different cells (e.g., CHO, HeLa, MDCK, 293, WI38, NIH-3T3, or HEK293) may be selected to have specific cellular and characteristic mechanisms for such post-translational activity to ensure correct modification and processing of the soluble ENPP1 polypeptide.

[0216] As used herein, the percentage of "identity" between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage of sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, or CLUSTAL OMEGA software. In some embodiments, alignment is performed using CLUSTAL OMEGA software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.

[0217] 8. Solubility Determination In some embodiments, the activity of soluble ENPP1 polypeptides can also be tested in cell-based or in vivo assays. For example, the effect of soluble ENPP1 polypeptides on the production of inorganic pyrophosphate (PPi) can be measured. Specifically, the pyrophosphatase / phosphodiesterase domain of ENPP1 protein hydrolyzes extracellular nucleotide triphosphates to generate inorganic pyrophosphate (PPi), which is generally soluble. This activity can be measured using pNP-TMP assays and HPLC-based ATP hydrolysis assays as previously described (Saunders, et al., 2008, Mol. Cancer Ther. 7(10):3352-62; Albright, et al., 2015, Nat Comm. 6:10006). The effect of soluble ENPP1 polypeptides on the expression of genes involved in ENPP1-related diseases, such as ARHR2 (e.g., transcription of fibroblast growth factor 23 in osteoblasts and osteoclasts), can be evaluated. This can be done, optionally, in the presence of one or more nucleotide triphosphates, or other ENPP1 substrates, and cells can be transfected to produce soluble ENPP1 polypeptides. Similarly, soluble ENPP1 polypeptides can be administered to mice or other animals, and the effect on ENPP1-associated disease can be assessed using art-recognized methods.

[0218] In some embodiments, the ENPP1 polypeptide used according to the methods described herein is an isolated polypeptide. As used herein, an isolated protein or polypeptide is one that is separated from components of its natural environment. In some embodiments, the polypeptide of the present disclosure is purified to greater than 95%, 96%, 97%, 98%, or 99% purity, for example, as determined by electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) analysis. Methods for the assessment of purity are well known in the art [see, for example, Flatman et al., (2007) J. Chromatogr. B 848:79-87]. In some embodiments, the soluble ENPP1 polypeptide used according to the methods described herein is a recombinant polypeptide.

[0219] 9. ENPP1 Production The ENPP1 polypeptides of the present disclosure can be produced by a variety of techniques known in the art. For example, the polypeptides of the present disclosure can be synthesized using standard protein chemistry techniques, such as those described in Bodansky, M. Principles of Peptide Synthesis, Springer Verlag, Berlin (1993) and Grant GA (ed.), Synthetic Peptides: A User's Guide, WH Freeman and Company, New York (1992). In addition, automated peptide synthesizers are commercially available (e.g., Advanced ChemTech Model 396; Milligen / Biosearch 9600). Alternatively, the polypeptides of the present disclosure, including fragments and / or variants thereof, can be recombinantly produced using a variety of expression systems (e.g., E. coli, Chinese hamster ovary (CHO) cells, COS cells, baculovirus, yeast Pichia), as is well known in the art. Proteins can be produced in either adherent or suspension cells. In some embodiments, fusion proteins are expressed in CHO cells. To establish a stable cell line, the nucleic acid sequence encoding the ENPP1 construct is cloned into a suitable vector for large-scale protein production. In further embodiments, modified or unmodified polypeptides of the present disclosure can be produced by digestion of recombinantly produced full-length ENPP1 polypeptides, for example, by using proteases such as trypsin, thermolysin, chymotrypsin, pepsin, or paired basic amino acid converting enzymes (PACE). Computer analysis (e.g., using commercially available software, e.g., MacVector, Omega, PCGene, Molecular Simulation, Inc.) can be used to identify protein cleavage sites. Alternatively, such polypeptides can be produced from recombinantly produced full-length ENPP1 polypeptides using chemical cleavage (e.g., cyanogen bromide, hydroxylamine, etc.).

[0220] 10. Expression system Many expression systems are known and can be used to produce ENPP1 fusion proteins, including bacteria (e.g., E. coli and Bacillus subtilis), yeast (e.g., Saccharomyces cerevisiae, Kluyveromyces lactis, and Pichia pastoris), filamentous fungi (e.g., Aspergillus), plant cells, animal cells, and insect cells. The desired protein can be produced in a conventional manner, for example, from a coding sequence inserted into the host chromosome or a free plasmid.

[0221] Yeast can be transformed with the coding sequence of the desired protein in any of the usual ways (e.g., electroporation). Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente, 1990, Methods Enzymol. 194:182. Successfully transformed cells, i.e., cells containing the DNA construct of the present disclosure, can be identified by well-known techniques. For example, cells resulting from the introduction of an expression construct can be grown to produce ENPP1 polypeptide. Cells can be harvested, lysed, and their DNA content examined for the presence of DNA using methods such as those described by Southern, 1975, J. Mol. Biol, 98:503 and / or Berent, et al., 1985, Biotech 3:208. Alternatively, the presence of protein in the supernatant can be detected using antibodies.

[0222] Useful yeast plasmid vectors include pRS403-406 and pRS413-416, and are generally available from Stratagene Cloning Systems (La Jolla, Calif., USA); plasmids pRS403, pRS404, pRS405, and pRS406 are Yeast Integrating plasmids (Yips), which incorporate the yeast selectable markers I-11S3, TRP1, LEU2, and 1JRA3. Plasmid pRS413-416 is a Yeast Centromere plasmid (YCps).

[0223] Various methods have been developed to operably link DNA to a vector via complementary cohesive ends. For example, complementary homopolymer tracts can be added to the DNA segment to be inserted into the vector DNA. The vector and DNA segment are then joined by hydrogen bonds between the complementary homopolymer tails to form a recombinant DNA molecule.

[0224] Synthetic linkers containing one or more restriction sites provide an alternative method of joining DNA segments to vectors. DNA segments generated by endonuclease restriction digestion are treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding 3'-single-stranded ends by their 3'-5'-nucleolytic activity and fill in recessed 3'-ends by their polymerization activity.

[0225] Thus, the combination of these activities produces blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that can catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. As a result, the products of the reaction are DNA segments carrying polymer linker sequences at their ends. These DNA segments can be cut with appropriate restriction enzymes and ligated into expression vectors that have been cut with enzymes that produce ends that are compatible with those of the DNA segments.

[0226] Single stably transfected cell clones are then established and screened for high expression clones of the desired ENPP1 fusion protein. Screening of single cell clones for ENPP1 protein expression can be achieved in a high-throughput manner in 96-well plates using the synthetic enzyme substrate pNP-TMP previously described (Albright, et al., 2015, Nat Commun. 6:10006). Upon identification of high expression clones through screening, protein production can be achieved in shake flasks or bioreactors previously described in Albright, et al., 2015, Nat. Commun. 6:10006.

[0227] 11. ENPP1 purification Purification of ENPP1 can be achieved using a combination of standard purification techniques known in the art. After purification, ENPP1-Fc can be dialyzed into PBS supplemented with Zn2+ and Mg2+ (PBSplus) concentrated to 5-7 mg / ml and frozen in aliquots of 200-500 pl at -80°C. The aliquots can be thawed immediately prior to use and the specific activity of the solution adjusted to 31.25 au / ml (or approximately 0.7 mg / ml depending on the preparation) by dilution in PBSplus.

[0228] 12. Route and frequency of administration The polypeptide is administered to the subject acutely or chronically. In certain embodiments, the second dose of the soluble ENPP1 polypeptide or ENPP1 fusion polypeptide disclosed herein is administered to the subject about 2 days, about 4 days, about 1 week, or about 1 month later, or even less frequently, such as once every few months, or once a year or less. The frequency of the dose is easily apparent to those skilled in the art and depends on any number of factors, including, but not limited to, the type and severity of the disease being treated, and the type and age of the patient.

[0229] The amount or frequency of the dose may be selected so that the steady state level of plasma PPi is maintained at a constant or steady state level and / or to achieve a continuous level of plasma PPi that is either close to normal (2-3 μM) levels or is at normal levels (30-50% higher) and does not revert to the lower levels of PPi that the subject had prior to administration of the first dose of a construct disclosed herein.

[0230] Alternative ENPP1 agents may be administered at any suitable time interval, such as every 2 days, or every 4 days, weekly, or monthly, to achieve a constant level of ENPP1 enzymatic activity.

[0231] Alternatively, an ENPP1 agent according to the present disclosure is administered at appropriate time intervals, such as every two days, or every four days, or weekly or monthly, depending on monitoring one or more symptoms of the disease or disorder of the subject.

[0232] Without wishing to be bound by theory, it is believed that maintaining steady state plasma PPi concentrations at normal levels reduces and / or prevents the progression of pathological calcification in a subject.

[0233] In certain embodiments, the polypeptide is administered topically, locally, parenterally, or systemically to the subject, hi some embodiments, the polypeptide is administered subcutaneously.

[0234] As used herein, "parenteral administration" of a formulation includes any administration route characterized by physical intrusion of a target tissue and administration of an ENPP1 agent through intrusion in a tissue. Thus, parenteral administration includes, but is not limited to, administration of an ENPP1 agent by injection of a composition, application of a composition through a surgical incision, application of a composition through a tissue membrane-permeable non-surgical wound, and the like. In particular, parenteral administration is intended to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrasternal injection, and renal dialysis infusion techniques.

[0235] The dosing regimen may affect what constitutes an effective amount. For example, several divided doses, as well as staggered doses, may be administered over a given period (daily) or sequentially, or the doses may be continuously infused or bolus injected. Furthermore, the choice of the recited dose of the ENPP1 agent may be dictated by the exigencies of the therapeutic or prophylactic situation.

[0236] Administration of the compositions of the present disclosure (e.g., soluble ENPP1 polypeptides and fusion proteins thereof) to a patient, such as a mammal (i.e., human), can be carried out using known procedures at doses and for periods of time effective to treat the patient's disease or disorder. The effective amount of the recited dose of ENPP1 drug required to achieve a therapeutic effect can vary according to factors such as the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of treatment, other drugs, compounds, and materials used in combination with the compound, the state of the disease or disorder of the patient being treated, age, sex, weight, condition, general health, and medical history, and similar factors well known in the medical field. Dosage regimens may be adjusted to provide an optimal therapeutic response. The selected dosage is determined based on the biological activity of the therapeutic compound, which in turn depends on the half-life and plasma time area under the curve of the therapeutic compound.

[0237] 13. Prophylactic Administration In light of the disclosure herein, one of skill in the art will therefore understand that preventing a disease or disorder in a subject encompasses administering an ENPP1 polypeptide to the subject as a prophylactic measure against the disease or disorder.

[0238] The relative amounts of active ingredient (e.g., soluble ENPP1 polypeptide and its fusion protein), pharma- ceutically acceptable carrier, and any additional ingredients in the formulations disclosed herein will vary depending on the identity, size, and condition of the subject being treated, and further depending on the route by which the composition is administered. As an example, the composition may contain about 0.1% to about 100% (w / w) active ingredient.

[0239] 14. Diseases associated with low PPi In some embodiments, the present disclosure contemplates a method of reducing or preventing the progression of a disease caused by a lower level of plasma PPi in a subject in need thereof, the method comprising administering a therapeutically effective amount of a polypeptide disclosed herein to the subject to increase the subject's plasma PPi to normal levels (2-3 μM) or above normal levels (30-50% higher), and then subsequently maintaining the plasma PPi at a constant normal or above normal level. The method further comprises administering an additional therapeutically effective amount at intervals of 2 days, 3 days, 1 week, or 1 month to maintain the subject's plasma PPi at a constant normal or above normal level to reduce or prevent the progression of pathological calcification or ossification. In certain embodiments, the soluble ENPP1 polypeptide or ENPP1 fusion polypeptide disclosed herein can be used to increase pyrophosphate (PPi) levels in a subject having PPi levels lower than normal levels (about 2 μM). In other embodiments, the soluble ENPP1 polypeptide or ENPP1 fusion polypeptide disclosed herein may be used to reduce or prevent the progression of pathological calcification or ossification in subjects with lower than normal PPi levels. In some embodiments, the soluble ENPP1 polypeptide or ENPP1 fusion polypeptide disclosed herein may be used to treat ENPP1 deficiencies (e.g., GACI and ARHR2) manifested by reduced extracellular PPi concentrations in subjects. In certain embodiments, the steady-state level of plasma PPi achieved after administration of a first dose of the soluble ENPP1 polypeptide or ENPP1 fusion polypeptide disclosed herein is maintained for a period of at least 2 days, at least 4 days, at least 1 week, or at least 1 month.

[0240] In some embodiments, the present disclosure contemplates a method of reducing or preventing the progression of a disease caused by lower than normal levels of plasma PPi in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a soluble ENPP1 polypeptide or ENPP1 fusion polypeptide (e.g., SEQ ID NOs: 3-5) disclosed herein to increase and / or maintain the subject's plasma PPi at a level that is about 90%, 95%, 100%, 105%, 110%, 120%, 130%, 140%, or 150% of the normal PPi level. In certain embodiments, the method further comprises further administration of a polypeptide disclosed herein every 2 days, 3 days, 1 week, or 1 month to maintain the plasma PPi level at a level that is about 90%, 95%, 100%, 105%, 110%, 120%, 130%, 140%, or 150% of the normal PPi level, thus preventing the progression of pathological calcification or ossification.

[0241] 15. Treatment / Indications The recited doses of the ENPP1 agents disclosed herein may be used in the methods of treating, reversing, or preventing the progression of diseases associated with ENPP1 deficiency or ABCC6 deficiency disclosed herein.

[0242] In one aspect, the disclosure relates to administering to a subject having ENPP1 deficiency or ABCC6 deficiency an ENPP1 agent at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of ENPP1 in the subject's plasma or tissues.

[0243] In one aspect, the disclosure relates to administering an ENPP1 agent to a subject having ENPP1 deficiency or ABCC6 deficiency at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of Pi and / or PPi in the subject's plasma. Physiological levels of Pi and PPi in human serum (and mammals) are 1-3 mM and 2-3 μM, respectively.

[0244] In one aspect, the disclosure relates to a method for preventing or reducing the progression of vascular calcification in a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of vascular calcification in the subject.

[0245] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological calcification in a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of pathological calcification in the subject.

[0246] The recited doses of the ENPP1 agents disclosed herein may be used in the methods of treating, reversing or preventing the progression of diseases associated with pathological calcification disclosed herein.

[0247] In one aspect, the disclosure relates to administering to a subject having pathological calcification an ENPP1 agent at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of ENPP1 in the subject's plasma or tissue.

[0248] In one aspect, the disclosure relates to administering an ENPP1 agent to a subject having pathological calcification at a dose of about 0.2 mg per kilogram of subject, about 0.6 mg per kilogram of subject, or about 1.8 mg per kilogram of subject to restore physiological levels of Pi and / or PPi in the subject's plasma. Physiological levels of Pi and PPi in human serum (and mammals) are 1-3 mM and 2-3 μM, respectively.

[0249] In one aspect, the disclosure relates to a method for preventing or reducing the progression of vascular calcification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of vascular calcification in the subject.

[0250] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological calcification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of pathological calcification in the subject.

[0251] In one aspect, the disclosure relates to a method for preventing or reducing the progression of tissue calcification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0252] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological ossification in a subject, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0253] In one aspect, the disclosure relates to a method for preventing or reducing the progression of tissue calcification in a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0254] In one aspect, the disclosure relates to a method for preventing or reducing the progression of pathological ossification in a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

[0255] In one aspect, the disclosure relates to a method for increasing circulating pyrophosphate (PPi) in a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

[0256] In one aspect, the disclosure relates to a method for increasing pyrophosphatase activity in a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

[0257] In one aspect, the disclosure relates to a method for ameliorating one or more symptoms of ENPP1 deficiency or ABCC6 deficiency in a subject, the method comprising administering to a subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby ameliorating one or more symptoms of ENPP1 deficiency or one or more symptoms of ABCC6 deficiency in the subject.

[0258] In one aspect, the disclosure relates to a method for treating a subject having ENPP1 deficiency or ABCC6 deficiency, the method comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby treating the subject.

[0259] In certain aspects, the disclosure relates to the use of ENPP1 agents, such as, for example, polypeptides having the amino acid sequences set forth in SEQ ID NOs: 2, 3, 4, and 5.

[0260] In certain embodiments, pathological calcifications include kidney and bladder stones, dental pulp stones, gallstones, salivary gland stones, chronic calculous prostatitis, testicular microcalcifications, calcification in hemodialysis patients, atherosclerosis, malakoplakia, scleroderma (systemic sclerosis), calcinosis cutis, calcific aortic stenosis, calcific tendinitis, synovitis and arthritis, diffuse idiopathic osteophytosis, juvenile dermatomyositis, infantile generalized arterial hyperplasia, and the like. calcification (GACI), ossification of the posterior longitudinal ligament (OPLL), hypophosphatemic rickets, autosomal hypophosphatemic rickets (ARHR2), osteoarthritis, calcification of atherosclerotic plaque, chronic kidney disease (CKD), end stage renal disease (ESRD), pseudoxanthoma elasticum (PXE), ankylosing spondylitis, arteriosclerosis, calciphylaxis, and systemic lupus erythematosus.

[0261] In certain embodiments, the pathological calcification is selected from the group consisting of pseudoxanthoma elasticum (PXE) and calcification of atherosclerotic plaque.

[0262] In certain embodiments, the pathological calcification is selected from the group consisting of idiopathic infantile arterial calcification (IIAC) and calcification of atherosclerotic plaque.

[0263] In some embodiments, the present disclosure contemplates a method of reducing or preventing the progression of ectopic calcification of soft tissue, including reducing, ameliorating, or preventing vascular calcification, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a soluble ENPP1 polypeptide or ENPP1 fusion polypeptide disclosed herein.

[0264] In some embodiments, the present disclosure contemplates a method of reducing or preventing progression of a disease caused by an ENPP1 deficiency (e.g., GACI and ARHR2), the method comprising administering to a subject a therapeutically effective amount of a soluble ENPP1 polypeptide or an ENPP1 fusion protein (e.g., SEQ ID NOs: 2, 3, 4, and 5) disclosed herein. In some embodiments, the ENPP1 deficiency is in GACI. In some embodiments, the ENPP1 deficiency is in ARHR2.

[0265] In some embodiments, the present disclosure contemplates a method of reducing or preventing progression of a disease caused by ABCC6 deficiency (e.g., PXE), the method comprising administering to a subject a therapeutically effective amount of a soluble ENPP1 polypeptide or ENPP1 fusion protein (e.g., SEQ ID NOs: 2, 3, 4, and 5) disclosed herein. In some embodiments, the ABCC6 deficiency is PXE. In some embodiments, subjects with ABCC6 deficiency exhibit symptoms similar to those diagnosed with GACI or ARHR2.

[0266] In some embodiments, the present disclosure contemplates a method of reducing or preventing the progression of a disease caused by pathological calcification (e.g., GACI and ARHR2), the method comprising administering to a subject a therapeutically effective amount of a soluble ENPP1 polypeptide or ENPP1 fusion protein (e.g., SEQ ID NOs: 2, 9, 10, and 11) disclosed herein. In some embodiments, the subject exhibiting pathological calcification has an ENPP1 deficiency. In some embodiments, the subject exhibiting pathological calcification has an ABCC6 deficiency.

[0267] In certain embodiments, the polypeptide is a secreted product of an ENPP1 precursor protein expressed in a mammalian cell. In other embodiments, the ENPP1 precursor protein comprises a signal peptide sequence and an ENPP1 polypeptide, and the ENPP1 precursor protein undergoes proteolytic processing into a polypeptide disclosed herein. In some embodiments, in the ENPP1 precursor protein, the signal peptide sequence is conjugated to the N-terminus of the ENPP1 polypeptide. Upon proteolysis, the signal sequence is cleaved from the ENPP1 precursor protein to provide the ENPP1 polypeptide. In certain embodiments, the signal peptide sequence is selected from the group consisting of an ENPP1 signal peptide sequence, an ENPP2 signal peptide sequence, an ENPP7 signal peptide sequence, and an ENPP5 signal peptide sequence.

[0268] Those skilled in the art will understand that according to the present disclosure, including the methods detailed herein, the present disclosure is not limited to the treatment of a disease or disorder once established. In particular, symptoms of the disease or disorder do not have to be manifested to harm the subject, and in fact the disease or disorder does not have to be detected in the subject before treatment is administered. That is, significant pathology from the disease or disorder does not have to occur before the ENPP1 polypeptide of the present invention can provide benefits.

[0269] In certain aspects, the present disclosure relates to a method for preventing disease and disorders in a subject, where a soluble ENPP1 polypeptide or an ENPP1 fusion polypeptide disclosed herein can be administered to a subject prior to the onset of a disease or disorder, thereby preventing the disease or disorder from developing. Thus, the present disclosure relates to a method for preventing or delaying the onset or reducing the progression or growth of a disease or disorder in a subject, the method comprising administering an ENPP1 polypeptide to a subject prior to detection of the disease or disorder. In certain embodiments, an ENPP1 polypeptide is administered to a subject with a strong family history of the disease or disorder, thereby preventing or delaying the onset or progression of the disease or disorder.

[0270] 16. ENPP1 Polypeptide Sequence [Table 1-1] [Table 1-2] [Table 1-3] SEQ ID NO: 7 (Mouse NPP1 - NCBI accession NP_001295256.1) 1 MERDGDQAGH GPRHGSAGNG RELESPAAAS LLAPMDLGEE PLEKAERARP AKDPNTYKVL 61 SLVLSVCVLT TILGCIFGLK PSCAKEVKSC KGRCFERTFS NCRCDAACVS LGNCCLDFQE 121 TCVEPTHIWT CNKFRCGEKR LSRFVCSCAD DCKTHNDCCI NYSSVCQDKK SWVEETCESI 181 DTPECPAEFE SPPTLLFSLD GFRAEYLHTW GGLLPVISKL KNCGTYTKNM RPMYPTKTFP 241 NHYSIVTGLY PESHGIIDNK MYDPKMNASF SLKSKEKFNP LWYKGQPIWV TANHQEVKSG 301 TYFWPGSDVE IDGILPDIYK VYNGSVPFEE RILAVLEWLQ LPSHERPHFY TLYLEEPDSS 361 GHSHGPVSSE VIKALQKVDR LVGMLMDGLK DLGLDKCLNL ILISDHGMEQ GSCKKYVYLN 421 KYLGDVNNVK VVYGPAARLR PTDVPETYYS FNYEALAKNL SCREPNQHFR PYLKPFLPKR 481 LHFAKSDRIE PLTFYLDPQW QLALNPSERK YCGSGFHGSD NLFSNMQALF IGYGPAFKHG 541 AEVDSFENIE VYNLMCDLLG LIPAPNNGSH GSLNHLLKKP IYNPSHPKEE GFLSQCPIKS 601 TSNDLGCTCD PWIVPIKDFE KQLNLTTEDV DDIYHMTVPY GRPRILLKQH RVCLLQQQQF 661 LTGYSLDLLM PLWASYTFLS NDQFSRDDFS NCLYQDLRIP LSPVHKCSYY KSNSKLSYGF 721 LTPPRLNRVS NHIYSEALLT SNIVPMYQSF QVIWHYLHDT LLQRYAHERN GINVVSGPVF 781 DFDYDGRYDS LEILKQNSRV IRSQEILIPT HFFIVLTSCK QLSETPLECS ALESSAYILP 841 HRPDNIESCT HGKRESSWVE ELLTLHRARV TDVELITGLS FYQDRQESVS ELLRLKTHLP 901 IFSQED Sequence number 8 (Bovine NPP1 - NCBI accession NP_001193141.1) 1 MERDSCAGGG SRGGEGGRGP REGLAGNGRD PGPGRAAEAS GEPQAAASLL APMDLGEEPL 61 ERAARARPAK DPNTYKVLSL VLSVCVLTTI LGCIFGLKPS CAKEIKSCKG RCFERTFGNC 121 RCDAACVDLG NCCLDYQETC IEPERIWTCT KFRCGEKRLS RSLCSCSDDC KDKGDCCINH 181 GSVCRGEKSW AEEECDSIDE PQCPAGFETP PTLLFSLDGF RAEYLHTWGG LLPVISKLKT 241 CGTYTKNMRP VYPTKTFPNH YSIVTGLYPE SHGIIDNNIY ​​DPQMNANFAL KNKEKFNPEW 301 YKGEPIWLTA KYQGLKTGTF FWPGSDVKIN GIFPDIYKIY NVSVPFEERI LAILKWLQLP 361 KDERPHFYTL YLEEPDSSGH SYGPVSSEVI RALQRVDNMV GMLMDGLKEL NLHRCLNLIL 421 ISDHGMEQGS CKKYVYLNKY LGDTKDYKVV YGPAARLRPS DVPDKYYSFD YEGIAKNLSC 481 QEPNQHFKPY LKHFLPKRLH FAKNDRIERL TFYLDPQWQL ALNPSERKYC GGGFHGSDNT 541 FLNMQALFIG YGPGFKHSTE VDSFENIEVY NLMCDLLNLT PAPNNGTHGS LNHLLSNPVY 601 TPKHPKEVRP LVQCPFTRAP RESLDCSCDP SILPIVDFQT QLNLTMAEEK TIKRGALPYG 661 RPRVLQNSTV CLLYQHQFVS GYSRDILMPL WTSYTIGRND SFSTEDFSNC LYQDLRIPLS 721 PVHKCSFYKN NAKLSYGLLS PPQLHKGSSQ VYSEALLTTN IVPMYQSFQV IWHYLHGTLL 781 QRYAEERNGL NVVSGPVFDS DYDGRYDSLE TLKQNSKIIR NLEVLIPTHF FLVLTSCKNT 841 SQTPLQCENL DAMAFILPHK TDNSESCAHG KHESLWVEEL LKLHTARITD VEHITGLSFY 901 QERKEPISDI LKLKTHLPTF NQED SEQ ID NO: 9 (Rabbit NPP1 - NCBI accession NP_001162404.1) 1 MERDGCAGGG SRGGEGGRAP REGPAGNSRD PGRSHAAEAP GNPQAAASLL APMDVGEEPL 61 EKAARARTAK DPNTYKVLSL VLSVCVLTTI LGCIFGLKPS CAKEVKSCKG RCFERTFGNC 121 RCDAACVELG NCCLDYQETC IEPEHIWTCN KFRCGEKRLT RSLCACSDDC KDQGDCCINY 181 SSVCQGEKSW VEEPCESINE PQCPAGFETP PTLLFSLDGF RAEYLHTWGG LLPVISKLKK 241 CGTYTKNMRP VYPTKTFPNH YSIVTGLYPE SHGIIDNKMY DPKMNASFSL KSKEKFNPEW 301 YKGEPIWVTA KYQGLKSGTF FWPGSDVEIN GIFPDIYKMY NGSVPFEERI LAVLQWLQLP 361 KDERPHFYTL YLEEPDSSGH SYGPVSSEVI KALQRVDNMV GMLMDGLKEL NLHRCLNLIL 421 VSDHGMEQGS CKKYIYLNKY LGDVKNIKVI YGPAARLRPS DVPDKYYSFN YEGIARNLSC 481 REPNQHFKPY LKHFLPKRLH FAKSDRIEPL TFYLDPQWQL ALNPSERKYC GSGFHGSDNI 541 FSNMQALFVG YGPGFKHGIE VDTFENIEVY NLMCDLLNLT PAPNNGTHGS LNHLLKNPVY 601 TPKHPKEVHP LIQCPFTRNP RDNLGCSCNP SILPIEDFQT QFNLTVAEEK NIKHETLPYG 661 RPRVLQKKNT ICLLSQHQFM SGYSQDILMP LWTSYTVDRN DSFSTEDFSN CLYQDFRISL 721 SPVHKCSFYK NNTKVSYGFL SPPQLNKNSR GIYSEALLTT NIVPMYQSFQ VIWRYFHDTL 781 LRKYAEERNG VNVVSGPVFD FDYDGRYDSL EILRQKRRVI RNQEILIPTH FFIVLTSCKD 841 ASQTPLHCEN LDTLAFILPH RTDNSESCLH GKHESSWVEE LLMLHRARIT DVEHITGLSF 901 YQQRKEPVSD ILKLKTHLPT FSQED SEQ ID NO: 10 (Babino NPP1 - NCBI accession NP_001076211.2) 1 MERDGCAGGG SQGGGKGGRG PREGLAGNGR DPSHGQASEA PGDPQAAASL LAPMDLGEEP 61 LEKAAGARPA KDPNTYKVLS LVLSVCVLTT ILGCIFGLKP SCAKEVKSCK GRCFERTFGN 121 CRCDVACVDL GNCCLDYQET CIEPERIWTC NKFRCGEKRL SRSLCACSDD CKERGDCCIN 181 YSAVCQGEKS WVEETCENIN EPQCPEGFEM PPTLLFSLDG FRAEYLHTWG GLLPVISKLK 241 KCGTYAKNMR PVYPTKTFPN HYSIVTGLYP ESHGIIDNKM YDPKMNASFS LKSKEKFNPE 301 WYKGEPIWLT AKYQGLRSGT FFWPGSDVKI NGIFPDIYKI YNGSVPFEER ILAILKWLRL 361 PKDERPHFYT LYLEEPDSSG HSYGPVSSEV IKALQRVDNM VGMLMDGLKE LNLHQCLNLI 421 LISDHGMEQG SCKKYIYLNK YLGDTKNIKV IYGPAARLRP SDVPEKYYSF NYENIARNLS 481 CREPNQHFKP YLKHFLPKRL HFAKSDRIEP LTFYLDPQWQ LALSPSERKY CGSGFHGSDN 541 VFSNMQALFV GYGPGFQHGI EVDSFENIEV YNLMCDLLNL TPAPNNGTHG SLNHLLKNPI 601 YTPKHPKEVQ PSVQCPLAGS PRDSLGCSCN PSILPIVDFQ TQFNLTTAEE KNINRASLPY 661 GRPRLLQKKS SVCLLYQHQF VSGYSHDVLM PLWTSYTVNR NDSFSTEDFS NCLYQDLRIS 721 FSPIHNCSFY KNNAKLSYGF LSPPQLSKDS SQIYSEALLT SNIVPMYQSF QVIWRYFHDT 781 LLQRYAEERN SINVVSGPVF DSDYDGRYDS SEALKRNRRV IRNQEILIPT HFFIVITSCK 841 NTSQTPLQCD NLDPLAFILP HRSDNSESCV HEKRESSWIE ELLMMHRARI MDVEHITGLS 901 FYQERKEPVS DILKLKTHLP TVSQED

[0271] 17. Treatment Protocol The following protocols may be used as guidance for ENPP1 enzyme replacement therapy at the listed dosages of ENPP1 agents, if deemed appropriate by a medical professional. The treatment protocols presented herein rely on the use of abbreviations, the full names of which are provided in Table 2.

[0272] a. Prohibited Drugs or Therapies** Patients exposed to treatment with an ENPP1 agent should discontinue use of oral phosphate and vitamin D3 or analogs prior to the first dose of the ENPP1 agent (e.g., at least 14 days prior to the first dose) and are prohibited throughout the treatment period. Oral phosphate therapy may be tapered to avoid hypercalciuria. Vitamin D metabolites or analogs may be discontinued without titration. Oral bisphosphonates should be discontinued 6 months prior to administration of the first dose.

[0273] Additional prohibited medications throughout the treatment period are: Bisphosphonates Anti-FGF23 (e.g., burosumab) Calcium receptor agonists Antacids Systemic corticosteroids PTH suppressors

[0274] b.Treatment frequency The ENPP1 agent is administered at least once or twice every other month, at least once or twice a month, three times a month, or at least once or twice a week.

[0275] The first dose of the ENPP1 agent may be administered on day 1. On days 8 through 29, and thereafter, the ENPP1 agent is administered to the subject twice weekly at the selected dose of mg / kg dose of the ENPP1 agent. Doses may be administered at approximately the same time on each administration day. Injection sites are alternated, with no injections within 2 inches of any previous injection site within the past two weeks.

[0276] The selected dose of the ENPP1 agent of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg is administered SC for a period of time determined by a medical professional skilled in the field of ENPP1 replacement therapy. The first dose of the ENPP1 agent may be administered on day 1. After the first dose, the subject may be observed for 7 days to monitor safety and collect PK samples. From day 8 to day 29, the subject receives the selected dose twice weekly. Administration of the ENPP1 agent at the selected dose is continued if deemed appropriate by the medical professional.

[0277] Subjects may receive eight doses of the ENPP1 agent over the course of a 29 day period, resulting in exposure of 1.6 mg, 4.8 mg, and 14.4 mg every 29 days for doses of 0.2 mg / kg, 0.6 mg / kg, and 1.8 mg / kg, respectively.

[0278] Similar to the endogenous ENPP1 enzyme, ENPP1 agents cleave ATP to generate AMP and PPi, thereby increasing plasma PPi levels and increasing AMP, which CD73 rapidly converts to adenosine. Supplementation of the endogenous human enzyme is intended to correct the inherent deficiency and allow for improved health and reduced clinical complications associated with ENPP1 deficiency.

[0279] C. Treatment evaluation i.Pharmacokinetics Determination of plasma concentration-time profile and non-compartmental PK parameters (including Tmax, Cmax, AUClast, AUCtau, AUCinf, T1 / 2, Cmin, Cl / F, and V / F) of ENPP1 drugs To evaluate the linearity between escalating ENPP1 drug SC doses and PK parameters.

[0280] ii.Pharmacodynamics Changes from baseline in plasma PPi levels, serum phosphate, plasma intact FGF23 levels, and TmP / GFR (adjusted for creatinine clearance) To evaluate the linearity between escalating ENPP1 SC doses and PD parameters Correlate changes in PPi and FGF23 -Correlate changes in PPi and TmP / GFR ·Correlate changes in FGF23 with changes in TmP / GFR -Detection of the presence and changes of blood and urine biomarkers - Plasma and urinary creatinine (used to calculate renal clearance of phosphate) - Serum 1,25(OH)2D, plasma ionized and total calcium, parathyroid hormone -Bone biomarkers: serum alkaline phosphatase (ALP), bone-specific ALP (BALP), carboxy-terminal cross-linked telopeptide of type I collagen (CTx), and N-terminal propeptide of procollagen type 1 (P1NP)

[0281] iii.Validity To assess the effectiveness of treatment, one or more of the following physical parameters may be determined before and during treatment: Baseline skeleton -Bone density using DEXA -Na 18 F-PET / HR-pQCT (or HR-CT) Baseline arterial and organ calcification -Na 18 F-PET / HR-pQCT (or HR-CT) -Echocardiogram Baseline cardiovascular and peripheral vascular reactivity function - Stress Doppler echocardiography -ECG -Ankle-brachial index -Pulse Wave Velocity -Peripheral Arterial Tonometry (PAT) -HRpQCT (or HR-CT), with and without contrast Baseline neurological function -NIH Stroke Score - Neurological examination Baseline lung function -Standard pulmonary function test Baseline performance outcomes -2MWT, 6MWT -Handheld dynamometry, grip strength, range of motion --Hearing tests: physical examination and otoscopic examination, impedance hearing test (tympanometry), pure tone hearing test (PTA), high frequency hearing test (HFA) Baseline patient, clinician, and caregiver outcomes - Patient and Physician Global Impressions of Change (CGI-C and CGI-S) -Gross Motor Function Classification System - Expanded and Revised -PROMIS Pain Interference and Pain Intensity -PROMIS Fatigue, Mobility, Cognitive Impact, Upper Extremity -Western Ontario-McMaster Universities Osteoarthritis Index (WOMAC) stiffness score Baseline renal calcification as measured by renal ultrasound Baseline bone histomorphometry using bone biopsy (optional) Baseline optical coherence tomography of the aortic, coronary, carotid, and renal arteries and vascular beds.

[0282] iv. Safety and immunogenicity Safety assessments may be summarized at baseline and at each observed time point. Safety variables include: Incidence, frequency, and severity of adverse events (AEs), treatment-related AEs, and serious adverse events (SAEs) Vital signs and weight Physical Examination Estimated glomerular filtration rate (eGFR) Laboratory tests, including chemistry, hematology, and urinalysis, including additional biochemical parameters of interest Anti-ENPP1-FC antibody testing and dose-limiting toxicity (DLT) -Incidence of any anti-drug antibodies (ADA) Incidence of TEAEs related to hypersensitivity reactions Concomitant medications Electrocardiogram (ECG) [Table 2-1] [Table 2-2] EXAMPLES

[0283] The invention will now be generally described, which will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of particular embodiments and aspects of the invention and are not intended to limit the invention.

[0284] Example 1. Generation of ENPP1 fusion proteins One example of an ENPP1 fusion protein is ENPP1-Fc, however the exemplification of ENPP1-Fc can be applied to other ENNPP1 fusion proteins presented herein.

[0285] ENPP1-Fc is a recombinant fusion protein containing the extracellular domain of human ENPP1 (soluble ENPP1) linked to the Fc fragment of IgG1 (rhENPP1-Fc). The recombinant extracellular domain of ENPP1-Fc, including its catalytic activity, is identical to the native ENPP1 enzyme. ENPP1-Fc is a recombinant human protein produced in CHO cells via an animal-derived component-free cell fed-batch process. The molecular weight of the ENPP1-Fc dimer is approximately 290 kDa, and ENPP1-Fc is highly glycosylated with a pI of approximately 6.0. Similar to endogenous ENPP1, the primary substrate of ENPP1-Fc is ATP, which is cleaved into AMP and PPi.

[0286] In a particular embodiment, the soluble ENPP1 protein was fused to a linker and human Fc domain via a linker (comprising leucine, isoleucine, and asparagine). Three ENPP1-Fc constructs are shown in Table 1 as SEQ ID NOs: 3, 4, and 5, which were purified from CHO cells.

[0287] Purification of ENPP1-Fc can be achieved by a series of column chromatography steps, including, for example, three or more of protein A chromatography, Q Sepharose chromatography, phenyl sepharose chromatography, size exclusion chromatography, and cation exchange chromatography, in any order. Purification can be completed with virus filtration and buffer exchange. After purification of the protein, the catalytic activity of the ENPP1-Fc protein can be evaluated using pNP-TMP as a chromogenic substrate.

[0288] Example 2: Treatment ENPP1-FC is administered at one of the following selected doses: 0.2 mg / kg, 0.6 mg / kg, and 1.8 mg / kg, subcutaneously (SC) once or twice every other month, at least once or twice a month, three times a month, or at least once or twice a week.

[0289] The first dose of the ENPP1-FC agent may be administered on day 1. On day 8 and thereafter, the ENPP1-Fc agent is administered to the subject twice weekly at the selected dose of mg / kg dose of the ENPP1 agent. Doses may be administered at approximately the same time on each administration day. Injection sites are alternated, with no site within 2 inches of any previous injection site within the past two weeks.

[0290] The selected dose of ENPP1-FC is one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC. The first dose of ENPP1-FC agent may be administered on day 1. After the first dose, subjects may be observed for 7 days to monitor safety and collect PK samples. On day 8 and thereafter, subjects receive the selected dose twice weekly. Administration of ENPP1-Fc at the selected dose is continued if deemed appropriate by a medical professional.

[0291] Subjects may receive eight doses of ENPP1-FC over the course of a 29 day period, for example, 0.2 mg / kg, 0.6 mg / kg, and 1.8 mg / kg doses resulting in exposures of 1.6 mg, 4.8 mg, and 14.4 mg every 29 days, respectively. Alternatively, subjects may receive as many as eight doses, as deemed appropriate by a medical professional.

[0292] Similar to the endogenous ENPP1 enzyme, ENPP1-FC cleaves ATP to generate AMP and PPi, thereby increasing plasma PPi levels and increasing AMP, which CD73 rapidly converts to adenosine. Supplementation of the endogenous human enzyme is intended to correct the inherent deficiency and allow for improved health and reduced clinical complications associated with ENPP1 baseline patient, clinician, and caregiver outcomes.

[0293] Example 3: Treatment of patients with ENPP1 deficiency Enpp1-Fc will be administered to patients identified as having ENPP1 deficiency by subcutaneous injection twice weekly starting on days 1 and 8 using selected doses as follows: [Table 3]

[0294] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. The patient's response to enzyme replacement is monitored where appropriate, e.g., following reduction in one or more symptoms of ENPP1 deficiency, and / or as determined by a medical professional using the guidance provided herein.

[0295] Example 4: Treatment of Patients Diagnosed with GACI Enpp1 deficiency may be masked as GACI, a rare disease that occurs in infants and is associated with widespread arterial calcification (Albright, et al., 2015, Nature Comm. 10006).

[0296] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. GACI patient response is monitored as appropriate, e.g., following reduction in one or more symptoms of GACI, and / or as determined by a medical professional using the guidance provided herein.

[0297] Example 5: Treatment of Patients Diagnosed with ARHR2 Enpp1 deficiency can be masked as ARHR2, a rare skeletal disorder characterized by low levels of plasma PPi and serum phosphate, which can lead to rickets, repeated fractures of long bones, rachitic skeletal deformities, and impaired growth and development (Ferreira et al. 2014, Moran 1975, Rutsch et al. 2008).

[0298] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. ARHR2 patient response is monitored as appropriate, e.g., following reduction in one or more symptoms of ARHR2, and / or as determined by a medical professional using the guidance provided herein.

[0299] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0300] Example 6: Treatment of patients with ABCC6 deficiency Enpp1-Fc will be administered to patients identified as having ABCC6 deficiency by subcutaneous injection twice weekly starting on days 1 and 8 using selected doses as follows: [Table 4] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. The patient's response to enzyme replacement is monitored where appropriate, e.g., following reduction in one or more symptoms of ABCC6 deficiency, and / or as determined by a medical professional using the guidance provided herein.

[0301] Example 7: Treatment of patients (female and male) diagnosed with PXE with ABCC6 deficiency A Phase 1 / 2, open-label, multiple-dose escalation study will be conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701, followed by an open-label long-term extension period in adults with ABCC6 deficiency manifesting as pseudoxanthoma elasticum (PXE). [Table 5]

[0302] Outcome measures The primary and secondary outcome measures were: Primary outcome measures: 1. Number of treatment-emergent adverse events (TEAEs) [time frame: 32 days (dose evaluation period)] A treatment-emergent AE is defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701. 2. Number of treatment-emergent adverse events (TEAEs) [Time frame: 52 weeks (Day 1 to Safety Follow-up Visit)] A treatment-emergent AE is defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701.

[0303] Secondary outcome measures : 1. Incidence of Anti-Drug Antibodies (ADA) [Time Frame: 32 days (dose evaluation period)] The presence of ADA is assessed and, if present, further evaluation determines the specificity and subtype. 2. Incidence of Anti-Drug Antibodies (ADA) [Time Frame: 52 weeks (Day 1 to Safety Follow-up Visit)] The presence of ADA is assessed and, if present, further evaluation determines the specificity and subtype. 3. Area under the plasma concentration vs. time curve (AUC) of INZ-701 [Time frame: 32 days (dose evaluation period)] For each subject, the variation in concentration of INZ-701 in plasma will be measured via serial blood samples obtained throughout the study and compared to the subject's baseline values ​​over time. 4. Maximum plasma concentration (Cmax) of INZ-701 [Time frame: 32 days (dose evaluation period)] For each subject, the maximum concentration of INZ-701 in plasma will be measured via serial blood samples obtained throughout the study and compared to the subject's baseline values ​​over time. 5. Systemic clearance of INZ-701 [Time frame: 32 days (dose evaluation period)] For each subject, clearance of INZ-701 from the body will be measured via serial blood samples obtained throughout the study and compared to the subject's baseline values ​​over time. 6. Change from baseline in plasma inorganic pyrophosphate (PPi) levels [Time frame: 32 days (dose evaluation period)] For each subject, plasma PPi is measured via serial blood samples obtained throughout the study to compare the subject's baseline values ​​over time. 7. Change from baseline in plasma inorganic pyrophosphate (PPi) levels [Time frame: 52 weeks (baseline to safety follow-up visit)]. For each subject, plasma PPi is measured via serial blood samples obtained throughout the study to compare the subject's baseline values ​​over time.

[0304] Eligibility Criteria Age eligibility for study: 18 to 64 years Eligible genders for study: All Gender-based: None Accepting healthy volunteers: No

[0305] Inclusion and Exclusion Criteria The inclusion and exclusion criteria were as follows: Selection criteria: 1. Written or electronic consent must be provided in accordance with ICH GCP after the nature of the clinical trial has been explained and prior to any study-related procedures 2. The clinical diagnosis of PXE is supported by the previous genetic identification of biallelic ABCC6 mutations 3. Male or female aged 18-<65 years at screening 4. Plasma PPi <1300 nM at screening 5. Subjects being treated with a statin or proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor must have been receiving a stable dose for 3 years prior to enrollment, unless the investigator, in consultation with the sponsor, determines that the change would not confound the interpretation of the study data. 6. At screening, women of childbearing potential (WOCBP) must have a negative serum pregnancy test 7. WOCBPs and male partners of fertile potential who are WOCBPs must agree to use one highly effective method of contraception and one barrier method from at least 1 month prior to the first dose of INZ-701 until 30 days (more than 5 half-lives of INZ-701) after the last dose of INZ-701. WOCBPs and male partners of fertile potential who are WOCBPs must also agree to not donate eggs for the period after the first dose of INZ-701 until 30 days after the last dose of INZ-701. 8. Sexually active men must agree to use condoms from the time after the first dose of INZ-701 until 30 days after the last dose of INZ-701. Men must also agree to not donate sperm from the time after the first dose of INZ-701 until 30 days after the last dose of INZ-701. 9. In the opinion of the investigator, must be willing and able to complete all aspects of the study 10. Agree to provide access to relevant medical records

[0306] Exclusion criteria: 1. The presence of any clinically significant disease (other than a disease considered to be associated with a diagnosis of ABCC6 deficiency) that, in the opinion of the investigator, may prevent study participation or confound interpretation of the study results, including known uncontrolled thyroid disease or unrelated connective tissue, bone, mineral, ophthalmologic, or muscular disease. 2. Progressive eye disease requiring anti-VEGF treatment at screening 3. Clinically significant abnormal laboratory results at screening. 4. Screening test results showing elevated aspartate aminotransferase, alanine aminotransferase, bilirubin (unless due to Gilbert's disorder), eGFR >60, 25-hydroxyvitamin D (25[OH]D) level <20 ng / mL, parathyroid hormone (PTH) >40% above the upper limit of normal, or significant hypercalcemia or hypocalcemia. Note: Rescreening for certain evaluations is permitted as described in the protocol. 5. Known active fungal, bacterial, and / or viral infection, including human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or COVID-19 virus. A negative COVID-19 test result is required within 5 days prior to the first dose of INZ-701. 6. Malignant tumor within the past 5 years, excluding non-melanoma skin cancer or cervical intraepithelial neoplasia. 7. Known intolerance to INZ-701 or any of its excipients. 8. Unable or unwilling to discontinue use of prohibited medications provided in the protocol (examples include bisphosphonates, calcilytics, antacids, systemic corticosteroids, pyrophosphate-containing medications). Discontinuation should only be undertaken if not deemed harmful and ordered by the subject's treating physician. 9. Receive any other investigational drug within 5 half-lives of the last dose of any other investigational drug, or 4 weeks prior to the first dose of INZ-701, whichever is longer, or from use of the investigational device until completion of study participation. 10. Symptoms since last COVID-19 vaccination within 14 days prior to the first dose of INZ-701, or any symptoms listed in the Inozyme COVID-19 Vaccine Guidance Document. 11. Subjects who are pregnant, attempting to become pregnant, or breastfeeding. 12. The person who is looking to become the father of a child.

[0307] Example 8: Treatment of patients diagnosed with GACI with ABCC6 deficiency ABCC6 deficiency can be masked as GACI. GACI is a rare disease that occurs in infants and is associated with extensive arterial calcification (Albright, et al., 2015, Nature Comm. 10006). GACI is thought to occur due to ENPP1 protein deficiency. Surprisingly, in some cases, the GACI phenotype is observed even when the subject has ABCC6 deficiency. Patients with ABCC6 deficiency can be identified by using isolated DNA samples using the protocol described in J Med Genet. 2007 Oct; 44(10): 621-628. (Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum, Ellen G Pfendner, et al)

[0308] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. Response of GACI patients (having ABCC6 deficiency) is monitored as appropriate, e.g., following reduction in one or more symptoms of GACI, and / or as determined by a medical professional using the guidance provided herein.

[0309] Example 9: Treatment of Patients Diagnosed with ARHR2 with ABCC6 Deficiency ABCC6 deficiency can be masked as a symptom of ARHR2. ARHR2 is a rare skeletal disorder characterized by low levels of plasma PPi and serum phosphate, which can lead to rickets, repeated fractures of long bones, rachitic skeletal deformities, and impaired growth and development (Ferreira et al. 2014, Moran 1975, Rutsch et al. 2008). In some subjects, ARHR2 phenotype is observed when the subject has ABCC6 deficiency. Patients with ABCC6 deficiency can be identified according to the procedure in Example 4.

[0310] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. ARHR2 patient response is monitored as appropriate, e.g., following reduction in one or more symptoms of ARHR2, and / or as determined by a medical professional using the guidance provided herein.

[0311] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0312] Example 10: Treatment of Patients Diagnosed with Chronic Kidney Disease (CKD) Pathological calcification can manifest as a separate disease state called CKD. Clinical symptoms of chronic kidney disease include itching, muscle spasms, nausea, lack of appetite, swelling of the feet and ankles, insomnia, and difficulty breathing. Chronic kidney disease, if left untreated, tends to progress to end-stage renal disease (ESRD). (Chronic Kidney Disease Diagnosis and Management: A Review, Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1; 322(13): 1294-1304.)

[0313] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. CKD patient response is monitored as appropriate, e.g., following reduction in one or more symptoms of CKD, and / or as determined by a medical professional using the guidance provided herein.

[0314] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0315] Example 11: Treatment of patients diagnosed with ossification of the posterior longitudinal ligament (OPLL) Pathologic calcification may manifest as a separate disease state called OPLL. Clinical symptoms and signs caused by OPLL are classified into (1) myelopathy, or spinal cord lesion with motor and sensory disturbances in the upper and lower limbs, spasticity, and bladder dysfunction, (2) cervical radiculopathy with pain and sensory disturbances in the upper limbs, and (3) axial discomfort with pain and stiffness around the neck. The early and most common symptoms of OPLL include paresthesias and tingling in the hands, and clumsiness. (Wu JC, Chen YC, Huang WC. Ossification of the Posterior Longitudinal Ligament in Cervical Spine: Prevalence, Management, and Prognosis. Neurospine. 2018 Mar; 15 (1): 33-41.)

[0316] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. OPLL patient response is monitored as appropriate, e.g., following reduction in one or more symptoms of OPLL, and / or as determined by a medical professional using the guidance provided herein.

[0317] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0318] Example 12: Treatment of Patients Diagnosed with Hereditary Hypophosphatemic Rickets Pathologic calcification may manifest as a separate disease state called hereditary hypophosphatemic rickets (HHR). Clinical symptoms and signs caused by HHR are classified as (1) myelopathy, or spinal cord lesion with motor and sensory disturbances of the upper and lower limbs, spasticity, and bladder dysfunction, (2) cervical radiculopathy with pain and sensory disturbances of the upper limbs, and (3) axial discomfort with pain and stiffness around the neck. The most common symptoms of HHR include premature fusion of the skull bones (craniosynostosis) and dental abnormalities. The disorder may also cause abnormal bone growth where ligaments and tendons attach to joints (enthesopathy). In adults, hypophosphatemia is characterized by softening of the bones, known as osteomalacia. (Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi YA clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res.2005 Aug;58(2):329-33.)

[0319] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. HHR patient response is monitored as appropriate, e.g., following reduction in one or more symptoms of HHR, and / or as determined by a medical professional using the guidance provided herein.

[0320] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0321] Example 13: Treatment of Patients Diagnosed with X-Linked Hypophosphatemia (XLH) Pathologic calcification can manifest as a separate disease state called X-linked hypophosphatemia (XLH). X-linked dominant hypophosphatemic rickets, or X-linked vitamin D resistant rickets, is an X-linked dominant form of rickets (or osteomalacia) that differs from most cases of rickets in that vitamin D supplementation does not cure it. It can cause bone deformities, including short stature and genu varum (bow legs). It is associated with mutations in the PHEX gene sequence (Xp.22) and subsequent inactivity of the PHEX protein. (Carpenter TO,Imel EA,Holm IA,Jan de Beur SM,Insogna KL.A clinician's guide to Res.2015 Feb;30(2):394)

[0322] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. The response of the XLH patient is monitored as appropriate, e.g., following reduction in one or more symptoms of XLH, and / or as determined by a medical professional using the guidance provided herein.

[0323] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0324] Example 14: Treatment of Patients Diagnosed with Autosomal Dominant Hypophosphatemic Rickets (ADHR) Pathological calcification may manifest as a separate disease state called autosomal dominant hypophosphatemic rickets (ADHR). Clinical symptoms and signs caused by ADHR Poorly formed bone (rickets), bone pain, and dental abscesses. ADHR is caused by mutations in fibroblast growth factor 23 (FGF23). ADHR is characterized by impaired bone mineralization, rickets and / or osteomalacia, suppressed levels of calcitriol (1,25-dihydroxyvitamin D3), renal phosphate wasting, and low serum phosphate. Mutations in FGF23 render the protein more stable and uncleavable by proteases, resulting in enhanced biological activity of FGF23. Enhanced activity of FGF23 mutants reduces expression of sodium phosphate cotransporters NPT2a and NPT2c on the apical surface of proximal tubule cells, resulting in renal phosphate wasting. (Rowe PS.The wrickkened pathways of FGF23,MEPE and PHEX.Crit Rev Oral Biol Med.2004 Sep 1;15(5):264-81.)

[0325] ENPP1-Fc is administered at a selected dose of ENPP1-FC, one of 0.2 mg / kg, 0.6 mg / kg, or 1.8 mg / kg SC, at least twice weekly for a period of time determined by a medical professional. The response of the ADHR patient is monitored as appropriate, e.g., following a reduction in one or more symptoms of ADHR, and / or as determined by a medical professional using the guidance provided herein.

[0326] The following examples provide guidance for determining treatment protocols and efficacy in the context of the entire specification.

[0327] Example 15: Measurement of inorganic pyrophosphate in plasma Low plasma PPi levels are a hallmark of ENPP1 deficiency and are used as an indicator of therapeutic efficacy. ENPP1-Fc specifically cleaves ATP to generate AMP and PPi. The therapeutic goal of ENPP1 ERT is to normalize extracellular PPi levels and correct clinical abnormalities associated with ENPP1 deficiency.

[0328] PPi is measured by obtaining a patient's plasma sample. The determined PPi data can be used to adjust dose levels. PPi levels can also serve as a primary PD marker for PK / PD analysis.

[0329] The concentrations of Pi and PPi in mammals are 1 to 3 mM and 2 to 3 μM, respectively.

[0330] Example 16: Biomarkers Related to Bone Health In addition to low plasma PPi, patients with ENPP1 deficiency are biochemically characterized by low serum phosphate, high urinary phosphate, low renal TmP / GFR, normal calcium (Ca), low normal urinary Ca, normal 25-hydroxyvitamin D (25OHD), low normal 1,25(OH)2D, high BAP, high intact FGF23, and normal PTH (IOF2019).

[0331] Biomarkers that can be used as additional determinants of bone health in treated patients are shown in Table 3. [Table 6]

[0332] Example 17: Efficacy of treatment with ENPP1-Fc Treatment efficacy can be assessed by measuring plasma PPi and other plasma analytes such as FGF23, Pi, FGF23, Pi, TmP / GFR, serum alkaline phosphatase (ALP), bone-specific ALP (BALP), carboxy-terminal cross-linked telopeptide of collagen type I (CTx), and procollagen type 1 N-terminal propeptide (P1NP). These analyte measurements can be used as PD markers associated with ENPP1 deficiency to determine the efficacy of ENPP1-FC. Changes in these analytes can be described as changes from baseline and in a time-dependent manner over the course of treatment. Dose linearity of PK and PD parameters can also be assessed.

[0333] Changes from baseline in plasma PPi levels, FGF23 levels, and urinary phosphate excretion per creatinine clearance may be analyzed using paired difference t-tests to test the null hypothesis.

[0334] Example 18: Drug concentration measurement Additionally, blood samples can be obtained from the patient for measurement of ENPP1-FC concentrations in plasma and for subsequent determination of PK parameters after the first dose (i.e., single dose) and after multiple doses (i.e., steady state) and thereafter.

[0335] Example 19: Immunogenicity (anti-drug antibodies) If desired, immunogenicity against ENPP1-Fc may be measured using anti-drug antibodies (ADA). Immunogenicity testing may utilize a multi-tiered approach, and if ADA is detected in the initial screening, confirmatory testing may be performed to determine specificity. Samples may also be used to assess and further establish specificity confirmation (i.e., titer) and neutralizing antibody assays.

[0336] Example 20: Pharmacokinetic, Pharmacodynamic, and Exploratory Biomarker Analysis Pharmacokinetic analysis can be performed on the PK population, and PK parameters of ENPP1-FC can be summarized by treatment using descriptive statistics. Dose linearity of PK and PD parameters can also be assessed. PK / PD analysis, immunogenicity analysis, and exploratory biomarker analysis can be determined.

[0337] Example 21: Additional Determinants of Efficacy Restoration of normal levels of PPi is the primary indicator of the effectiveness of treatment with NEPP1-Fc, although other physical measurements may be used, if desired, to aid in determining the effectiveness of treatment. These include one or more of the following:

[0338] 1. X-ray and imaging X-rays of skeletal severity. Standard x-rays can be obtained to detect the skeletal deformities of rickets. Acquisition x-rays can be taken, for example, on the wrists and knees.

[0339] DEXA Scan. A DEXA scan can be used to assess changes in bone density.

[0340] Positron emission tomography-computed tomography. Baseline Na 18 F-PET / HRpQCT (or HR-CT) can be a whole-body scan performed within 1 month of the first dose of ENPP1-FC to measure arterial and organ calcification and skeletal abnormalities for baseline and future intervention assessment. 18 F-PET measures bone metabolism as well as arterial microcalcification. High-resolution quantitative computed tomography (HRQCT) or HR-CT can determine bone microarchitecture in the non-dominant distal extremity and tibia. Standard bone geometric parameters are calculated.

[0341] Doppler echocardiogram. A baseline echocardiogram can be obtained within 3 days before the first dose of ENPP1-FC. Doppler echo can be used to measure cardiac and valvular cardiac function [LVEF, blood flow] calcification, and arteriosclerosis.

[0342] Optical coherence tomography. Optical coherence tomography may be used to visualize neointimal proliferation.

[0343] Peripheral Arterial Tonometry. Peripheral arterial tonometry (PAT) can be used to assess digital pulse wave amplitude (PWA), which corresponds to digital stroke volume variation.

[0344] Renal ultrasound examination. Renal ultrasound examination can be used to measure kidney calcification, for example, within one week of starting ENPP1-FC.

[0345] Bone histomorphology and bone biopsy. A bone biopsy may be performed as a baseline measurement. A 10 day tetracycline challenge prior to bone biopsy is preferred.

[0346] 2. Walking ability. Walking tests can be used as submaximal exercise measures to measure functional capacity in ambulatory patients combining cardiopulmonary, neuromuscular, and musculoskeletal function. The 6-minute walk test (6MWT) was originally developed by the American Thoracic Society (ATS 2002) for use in adults and is now commonly used in both adult and pediatric populations (Mylius et al. 2016), as well as in children with neuromuscular diseases such as spinal muscular atrophy (Montes et al. 2018), Duchenne muscular dystrophy (McDonald et al. 2013), and infantile-onset Pompe disease (van der Meijden et al. 2018). The 2-minute walk test (2MWT) is included in the NIH toolbox and is increasingly used to measure the same characteristics.

[0347] The 6MWT and 2MWT may be administered to patients pre- and during treatment at the discretion of the healthcare provider. If a subject is unable to complete at least the 2MWT at baseline, additional assessments during treatment may be at the discretion of the healthcare provider. Resting heart rate is obtained pre- and post-test. Distance walked during the first 2 minutes and the entire 6 minutes of the 6MWT may be recorded. Distance walked during the 2 and 6 minutes may be compared to age- and sex-matched normative data (percentage of predicted value).

[0348] 3. Dynamometry. Strength may be assessed using dynamometry prior to and / or during treatment, at the discretion of the healthcare provider. Handheld dynamometry is a direct measurement of strength commonly used in both children and adults. Muscle groups that may be assessed include shoulder abduction, shoulder flexion, elbow flexion, elbow extension, hip abduction, hip flexion, hip extension, and knee extension. Each muscle group may be measured twice on both sides.

[0349] Grip. Grip strength may be measured using a grip strength dynamometer prior to and / or during treatment, at the discretion of the healthcare provider. Equipment and assessor instructions may be standardized across centers. Grip may be assessed bilaterally with one exercise and one maximum force measurement taken for each hand, and results may be compared to age- and sex-matched normative data (if available).

[0350] Range of Motion. Range of motion may be assessed using a goniometer, an instrument that tests joint angles and measures the degree of motion at a joint. The fixed arm of the goniometer aligns with a designated bony landmark on a fixed body segment, and the moving arm of the goniometer aligns with a designated bony landmark on the moving limb. A fulcrum of the goniometer is designated for each motion measured using the axis of motion and the bony landmark. Range of motion may be assessed for one or more of shoulder abduction, shoulder flexion, elbow flexion, elbow extension, hip abduction, hip flexion, hip extension, and knee extension.

[0351] 4. Hearing Testing. Moderate hearing loss is associated with ARHR2 (Brachet et al. 2014, Steichen-Gersdorf et al. 2015). Baseline hearing may be determined by one or more of the following: physical examination and otoscopy, impedance hearing test (commonly referred to as tympanometry), pure tone audiometry (PTA) (frequencies up to 8 kHz, if available). (If PTA thresholds are >15 dB, subjects should also undergo bone conduction testing), high frequency audiometry (HFA) (frequencies up to 16 kHz).

[0352] 5. Clinician Global Impression Scale. The Clinical Global Impression (CGI-S) scale was developed for use in clinical trials sponsored by the National Institute of Mental Health to provide a brief, independent assessment of the clinician's perspective of a patient's overall functioning before and after starting an investigational drug (Guy 1976). The CGI provides a clinician-determined overall summary measure that considers all available information, including knowledge of the patient's medical history, psychosocial situation, symptoms, behavior, and the impact of symptoms on the patient's ability to function. The CGI-S may be administered before and / or during treatment at the discretion of the healthcare provider and provides a global assessment of change using a 7-point scale ranging from -3 (severe worsening) to +3 (marked improvement).

[0353] 6. Gross Motor Function Classification System-Extended and Revised. The Gross Motor Function Classification System-Extended and Revised (GMFCS-E and R) may be administered prior to and / or during treatment at the discretion of the healthcare provider. GMFCS-E and R classify patient-initiated movements with an emphasis on mobility on a scale of 1 to 5.

[0354] 7. Patient-Reported Outcomes Measurement Information System. The Patient-Reported Outcomes Measurement Information System (PROMIS) is a set of questionnaires developed by the National Institutes of Health (NIH) to assess physical, mental, and social health from the patient's perspective ( http: / / www.healthmeasures.net). These questionnaires have been used in clinical trials in people with chronic health conditions such as X-linked hypophosphatemia, arthritis, multiple sclerosis, and neurofibromatosis. Each questionnaire contains 8-10 items that participants rate on a 5-point Likert scale ranging from 1 (never) to 5 (always). Scores on each questionnaire are summed, with higher scores indicating more measured domains (e.g., higher fatigue, higher physical function). Raw scores are converted to T-scores based on a mean of 50 and a standard deviation of 10, allowing comparison of the study sample to the general population. PROMIS scales may include Pain Interference (Short Form 8a), Pain Intensity (Version 3a), Physical Function-Upper Extremity (Custom Short Form), Physical Function-Mobility (Short Form 13a FACIT Fatigue), Fatigue (Short Form), and Cognitive Impact (Short Form 8a) and may be administered before and / or during treatment at the discretion of the healthcare provider. These assessments can be completed unassisted by the subject.

[0355] 8. Caregiver Global Impression Scale. The Caregiver Global Impression of Status may be administered to the patient's caregiver prior to and / or during treatment at the discretion of the healthcare provider. The Caregiver Global Impression of Change provides a global assessment of change using a 7-point scale ranging from -3 (severe deterioration) to +3 (marked improvement).

[0356] 9. Western Ontario-McMaster Universities Osteoarthritis Index. WOMAC is a patient-reported outcome measure used to assess activities of daily living, functional mobility, walking, general health, pain, and quality of life in patients with low back or knee pain ( www.sralab.org ). The assessment consists of 24 items and takes approximately 12 minutes to administer. The WOMAC may be administered before and / or during treatment, at the discretion of the healthcare provider. The assessment can be completed by the subject unassisted.

[0357] References ATS.American Thoracic Society Statement:Guidelines for the six-minute walk test.AmJRespir,CritCare Med.2002 2002;166(1):111-7. Brachet C, Mansbach AL, Clerckx A, Deltenre P, Heinrichs C. Hearing loss is part of the clinical picture of ENPP1 loss of function mutation. Horm Res Paediatr. 2014;81(1):63-6. CTFG.Recommendations related to contraception and pregnancy testing in clinical trials.2014 [19 May 2020]; Available from: http: / / www.hma.eu / fileadmin / dateien / Human_Medicines / 01- About HMA / Working Groups / CTFG / 2014 09 HMA CTFG Contraception.pdf . Ferreira C, Ziegler S, Gahl W.Generalized Arterial Calcification of Infancy.In:Adam MP,Ardinger HH,Pagon RA,Wallace SE,Bean LJH,Stephens K,et al.,editors.GeneReviews((R)).Seattle(WA)2014. Guy W.The Clinical Global Impression Scale.In:Rush Jr AJ,First MB,Blacker D,editors.Handbook of Psychiatric Measures,2008.Washington,DC:American Psychiatric Publishing,Inc;1976.p.90-2. IOF.Autosomal Recessive Hypophosphatemic Rickets Type 2(ARHR2).2019[19 May 2020]; Available from: https: / / www.iofbonehealth.org / osteoporosis-musculoskeletal-disorders / skeletal-rare-disorders / autosomal-recessive-hypophosphatemia-0. Mackenzie NC,Huesa C,Rutsch F,MacRae VE.New insights into NPP1 function:lessons from clinical and animal studies.Bone.2012 Nov;51(5):961-8. McDonald CM,Henricson EK,Abresch RT,Florence JM,Eagle M,Gappmaier E,et al.The 6-minute walk test and other endpoints in Duchenne muscular dystrophy:longitudinal natural history observations over 48 weeks from a multicenter study.Muscle Nerve.2013 Sep;48(3):343-56. Montes J,McDermott MP,Mirek E,Mazzone ES,Main M,Glanzman AM,et al. Ambulatory function in spinal muscular atrophy:Age-related patterns of progression.PLoS One.2018;13(6):e0199657. Moran JJ.Idiopathic arterial calcification of infancy:a clinicopathologic study.Pathol Annu.1975;10:393-417. Mylius CF,Paap D,Takken T.Reference value for the 6-minute walk test in children and adolescents:a systematic review.Expert Rev Respir Med.2016 Dec;10(12):1335-52. NCI.National Cancer Institute Division of Cancer Treatment and Diagnosis(DCTD),National Cancer Institute(NCI),National Institutes of Health(NIH),Department of Health and Human Services(DHHS).Common Terminology Criteria for Adverse Events V5.0(CTCAE).Release date:27 / 11 / 2017 https: / / ctep.cancer.gov / protocoldevelopment / electronic_applications / docs / ctcae_v5_quick_reference 8.5x11.pdf .2017. Orriss IR,Arnett TR,Russell RG.Pyrophosphate:a key inhibitor of mineralisation.Curr Opin Pharmacol.2016 Jun;28:57-68. Circ Cardiovasc Genet.2008: Rutsch F, Boyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, et al Dec;1(2):133-40. Steichen-Gersdorf E,Lorenz-Depiereux B,Strom TM,Shaw NJ.Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1.J Pediatr Endocrinol Metab.2015 Jul;28(7-8):967-70. van der Meijden JC,Kruijshaar ME,Harlaar L,Rizopoulos D,van der Beek N,van der Ploeg AT.Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.J Inherit Metab Dis.2018 Nov;41(6):1205-14.

[0358] Incorporation by Reference All publications and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0359] Other embodiments While specific embodiments of the subject matter have been discussed, the above specification is illustrative and not limiting. Many variations will become apparent to those skilled in the art upon review of this specification and the following claims. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

Claims

1. An ENPP1 drug for use in preventing or reducing the progression of pathological calcification in a subject having ENPP1 deficiency, comprising administering to the subject an ENPP1 drug at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of pathological calcification in the subject.

2. An ENPP1 agent for use in preventing or reducing the progression of pathological calcification in a subject having ABCC6 deficiency or a subject with ABCC6 deficiency, comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of pathological calcification in the subject.

3. An ENPP1 agent for use in increasing circulating pyrophosphate (PPi) or increasing pyrophosphatase activity in a subject having ENPP1 deficiency, comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

4. An ENPP1 agent for use in increasing circulating pyrophosphate (PPi) or increasing pyrophosphatase activity in a subject having ABCC6 deficiency or a subject having an ABCC6 deficiency, comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby increasing circulating PPi in the subject.

5. An ENPP1 agent for use in preventing or reducing the progression of tissue calcification in a subject having ENPP1 deficiency, comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

6. An ENPP1 agent for use in preventing or reducing the progression of tissue calcification in a subject having ABCC6 deficiency or a subject who is ABCC6 deficient, comprising administering to the subject an ENPP1 agent at a dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, thereby preventing or reducing the progression of tissue calcification in the subject.

7. The method of any one of claims 1 to 6, wherein the ENPP1 agent is administered to the subject at least once or at least twice a week.

8. The method of any one of claims 1 to 6, wherein the ENPP1 agent is administered subcutaneously to the subject.

9. The agent of any one of claims 1 to 6, wherein the ENPP1 agent is administered to the subject under a dosing regimen comprising: (a) an initial dose of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, and (b) a maintenance dose of the ENPP1 agent of about 0.2 mg per kilogram of the subject, about 0.6 mg per kilogram of the subject, or about 1.8 mg per kilogram of the subject, administered twice weekly for about 7 days after the initial dose, preferably wherein the initial dose and the maintenance dose are the same.

10. The agent according to any one of claims 1 to 6, wherein the ENPP1 agent comprises the extracellular domain of ENPP1 and / or the ENPP1 agent comprises a heterologous moiety.

11. The agent of claim 10, wherein the heterologous moiety is a polypeptide and / or the heterologous moiety increases the circulating half-life of the ENPP1 agent relative to the circulating half-life of the ENPP1 agent lacking the heterologous moiety.

12. The agent according to claim 11, wherein the heterologous moiety comprises an Fc region of an immunoglobulin molecule, preferably the immunoglobulin molecule is a human immunoglobulin molecule and / or the immunoglobulin molecule is IgG1.

13. The agent of claim 11 , wherein the heterologous moiety comprises albumin.

14. The ENPP1 agent is a) comprising amino acid residues 99 (PSCAKE) to 925 (QED) of SEQ ID NO:1 [ENPP1 ECD]; b) comprising amino acid residues 1 (FTAGLKPSCAKE) to 833 (QED) of SEQ ID NO:3; c) comprising the amino acid sequence shown in SEQ ID NO:5; d) comprising the amino acid sequence shown in SEQ ID NO:3; e) comprising the amino acid sequence shown in SEQ ID NO:2; or f) A drug according to any one of claims 1 to 6, comprising the amino acid sequence shown in SEQ ID NO: 3, 4 or 5.

15. The method of claim 1, wherein the ENPP1 agent is administered to the subject by subcutaneous administration at least once per week or at least twice per week.

16. The method of any one of claims 1 to 6, wherein the subject has or is suspected of having generalized arterial calcification of infancy (GACI).

17. The method of any one of claims 1 to 6, wherein the subject has or is suspected of having pseudoxanthoma elasticum (PXE).

18. The method of any one of claims 1 to 6, wherein the subject exhibits symptoms similar to those of a person with autosomal recessive hypophosphatemic rickets type 2 (ARHR2) or generalized arterial calcification of infancy (GACI).

19. The subject may have kidney and bladder stones, dental pulp stones, gallstones, salivary gland stones, chronic calculous prostatitis, testicular microcalcification, calcification in hemodialysis patients, atherosclerosis, malakoplakia, scleroderma (systemic sclerosis), calcinosis cutis, calcific aortic stenosis, calcific tendinitis, synovitis and arthritis, diffuse idiopathic osteophytosis, juvenile dermatomyositis, generalized arterial calcification of infancy (GACI), ossification of the posterior longitudinal ligament (OLS), vascular endothelial cell carcinoma (VEDC), vascular endothelial cell carcinoma (VEDC), vascular endothelial cell carcinoma (VEC ... The drug according to any one of claims 1 to 6, which is for patients with or suspected of having one or more of the following: chronic kidney disease (CKD), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoarthritis, calcification of atherosclerotic plaques, chronic kidney disease (CKD), end stage renal disease (ESRD), pseudoxanthoma elasticum (PXE), ankylosing spondylitis, arteriosclerosis, calciphylaxis, and systemic lupus erythematosus.

20. The method according to any one of claims 1 to 6, wherein the subject exhibits calcification of soft connective tissue, and optionally the subject exhibits accumulation of deposits of calcium and other minerals (calcification) in elastic fibres of connective tissue.

21. The method according to any one of claims 1 to 6, wherein the subject presents calcifications in the eye, the cardiovascular system and / or the skin, preferably presents stenosis and / or arteriosclerosis of the arteries.

22. The method according to any one of claims 1 to 6, wherein the subject exhibits ectopic calcification and / or vascular narrowing of the lower limbs, and / or claudication.

23. The method of any one of claims 1 to 6, wherein the subject presents with an ocular abnormality, preferably the ocular abnormality comprises abnormal pigmentation of cells of the retina and / or angioid streaks and / or abnormalities of the elastic membrane beneath the retina.

24. The method according to any one of claims 1 to 6, wherein the subject exhibits choroidal neovascularization.

25. The method of any one of claims 1 to 6, wherein the subject presents with visual impairment, vision loss, and / or blindness and also presents one or more symptoms of soft tissue calcification.

26. The agent according to any one of claims 1 to 6, wherein the agent is administered as a pharmaceutical composition comprising about 0.2 to 1.8 mg of ENPP1-Fc per kg of the subject's weight as the sole active ingredient by subcutaneous administration.

27. The method of any one of claims 1 to 6, wherein the subject has not been diagnosed with a malignant tumor within the past 5 years prior to the administration of the ENPP1 agent.

28. The agent of any one of claims 1 to 6, wherein the subject is being treated with one or more statins and / or one or more proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors prior to the administration of the ENPP1 agent.

29. The agent of any one of claims 1 to 6, wherein the subject has not been diagnosed with a malignancy prior to administration of the ENPP1 agent, preferably the malignancy excludes non-melanoma skin cancer and cervical intraepithelial neoplasia.

30. The drug of claim 2, wherein the ABCC6 deficiency is pseudoxanthoma elasticum (PXE) and the ENPP1 drug is administered to the subject, thereby treating the PXE in the subject.